Scolaris Content Display Scolaris Content Display

Les psychothérapies pour les enfants et les adolescents exposés à un traumatisme

Contraer todo Desplegar todo

Résumé scientifique

Contexte

Les enfants et les adolescents ayant subi des traumatismes présentent un haut risque de développer un trouble de stress post‐traumatique (TSPT), de souffrir émotionnellement, d'avoir des problèmes comportementaux et des atteintes à leur santé mentale. Tous ces facteurs sont associés à des frais et des coûts personnels et médicaux. Un large éventail de psychothérapies est utilisé pour prévenir les effets négatifs associés à un traumatisme chez les enfants et les adolescents.

Objectifs

Évaluer les effets des psychothérapies dans la prévention des TSPT, des conséquences émotionnelles négatives, des troubles du comportement et des atteintes à la santé mentale chez les enfants et les adolescents ayant subi un événement traumatique.

Stratégie de recherche documentaire

Nous avons effectué des recherches dans le registre spécialisé du groupe Cochrane sur les troubles mentaux communs jusqu'au 29 mai 2015. Ce registre contient des rapports d'essais contrôlés randomisés pertinents issus de The Cochrane Library (toutes les années incluses), d'EMBASE (de 1974 à ce jour), de MEDLINE (de 1950 à ce jour) et de PsycINFO (de 1967 à ce jour). Nous avons également examiné les références bibliographiques des études et revues pertinentes. Nous n'avons pas limité les recherches en fonction de leur date de réalisation, de leur langue ou du statut de publication.

Critères de sélection

Tous les essais contrôlés randomisés comparaient des psychothérapies à une condition de contrôle telle que le traitement habituel, la participation à une liste d'attente, l'absence de traitement, un traitement pharmacologique ou encore d'autres traitements chez les enfants ou les adolescents ayant subi un événement traumatique.

Recueil et analyse des données

Deux des auteurs ont indépendamment extrait les données. Nous avons calculé les rapports de cotes pour les résultats binaires et les différences moyennes standardisées pour les résultats continus en utilisant un modèle à effets aléatoires. Nous avons analysé les données après les avoir séparées en 3 catégories, 1) les résultats au court terme (jusqu'à un mois inclus après le traitement), 2) les résultats au moyen terme (à partir d'un mois jusqu'à un an après le traitement) et 3) les résultats au long terme (à partir d'un an ou plus après le traitement).

Résultats principaux

Les investigateurs ont inclus 6201 participants dans les 51 essais inclus. Vingt études portaient uniquement sur des enfants, deux portaient uniquement sur des enfants d'âge préscolaire et dix uniquement sur des adolescents ; tous les autres essais ont inclus à la fois des enfants et des adolescents. Les participants ont été exposés à des abus sexuels dans 12 essais, à des situations de guerre ou à de la violence communautaire dans dix essais, à un traumatisme physique et à des catastrophes naturelles dans six essais, et à des violences interpersonnelles dans trois essais. Dans un essai les participants avaient souffert d'une maladie menaçant le pronostic vital et dans un autre ils avaient été victimes d'abus physiques ou de maltraitance. Les participants dans les essais restants ont été exposés à un éventail de traumatismes.

La plupart des essais comparaient une psychothérapie à une intervention contrôle tel que le traitement habituel, la participation à une liste d'attente ou l'absence de traitement. Dix‐sept essais utilisaient la thérapie cognitive‐comportementale (TCC), quatre utilisaient la thérapie familiale, trois faisaient appel à un débriefing, deux essais utilisaient la désensibilisation et le reconditionnement par mouvements oculaires (DRMO), deux autres la thérapie narrative, puis deux la psychoéducation et une thérapie de soutien, un essai incluait l'exposition et un dernier une TCC associée à un traitement narratif. Huit essais comparaient une TCC à une thérapie de soutien, deux comparaient une TCC à la DRMO, un essai comparait une TCC à une thérapie psychodynamique, un essai comparait l'exposition associée à un traitement de soutien à la thérapie de soutien seule et un dernier essai comparait la thérapie narrative associée à une TCC par rapport à une TCC seule. Quatre essais comparaient une psychothérapie offerte en individuel à la même thérapie offerte en groupe et un essai comparait une TCC pour l’enfant par rapport à une TCC à la fois pour la mère et pour l'enfant.

La probabilité d'obtenir un diagnostic de TSPT chez les enfants et les adolescents ayant reçu une psychothérapie était significativement réduite par rapport à ceux n'ayant reçu aucun traitement, ayant suivi un traitement habituel ou ceux qui étaient sur une liste d'attente jusqu'à un mois après le traitement (rapport des cotes (RC) 0,51 intervalle de confiance à 95 % (IC) 0,34 à 0,77 ; nombre de sujets à traiter pour obtenir un résultat bénéfique supplémentaire (NSTb) 6,25, IC à 95 % 3,70 à 16,67 ; cinq études ; 874 participants). Cependant, la qualité globale des preuves pour le diagnostic de TSPT a été considérée comme très faible. Les symptômes de TSPT ont également été significativement réduits un mois après le traitement (différence moyenne standardisée (DMS) ‐0,42, IC à 95 % ‐0,61 à ‐0,24 ; 15 études ; 2051 participants) et la qualité des preuves était faible. Ces effets des psychothérapies n'étaient pas apparents au long terme.

La TCC n'était pas plus ou moins efficace que la DRMO ou la thérapie de soutien pour réduire le nombre de diagnostics de TSPT à court terme (RC 0,74, IC à 95 % 0,29 à 1,91 ; 2 études ; 160 participants), mais ce résultat est fondé sur des preuves de très faible qualité. Par rapport à la réduction des symptômes de TSPT à court terme, il y avait un faible effet en faveur de la TCC comparée à la DRMO, la thérapie par le jeu et les thérapies de soutien (DMS ‐0,24, IC à 95 % ‐0,42 à ‐0,05 ; 7 études ; 466 participants). La qualité des preuves pour ce critère de jugement était jugée comme modérée.

Nous n'avons pas identifié d'études comparant des thérapies pharmacologiques avec des psychothérapies.

Conclusions des auteurs

Les méta‐analyses dans cette revue apportent des preuves concernant l'efficacité des psychothérapies dans la prévention des TSPT et la réduction des symptômes chez les enfants et les adolescents exposés à un traumatisme jusqu'à un mois après celui‐ci. Cependant, notre confiance dans ces résultats est limitée par la qualité des études incluses et par une hétérogénéité substantielle entre les études. Beaucoup plus de preuves sont requises pour démontrer l'efficacité relative des différentes psychothérapies pour les enfants exposés à un traumatisme, en particulier au long terme. Des études de haute qualité doivent être réalisées afin de comparer ces thérapies.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Les psychothérapies pour prévenir les troubles de stress post‐traumatique chez les enfants et les adolescents

Pourquoi cette revue est ‐elle importante ?

Les enfants et les adolescents ayant subi des traumatismes présentent un haut risque de développer un trouble de stress post‐traumatique (TSPT) ainsi que des souffrances psychologiques et sociales.

Qui sera intéressé par cette revue ?

Les enfants et les adolescents ayant subi un traumatisme, leurs familles ainsi que les aidants naturels seront intéressés par cette revue. Les professionnels de la santé le seront également, en particulier ceux travaillant dans des services de santé mentale pour les enfants et les adolescents.

Quelles sont les questions auxquelles cette revue souhaite répondre ?

• Quels sont les effets des psychothérapies dans la prévention des TSPT et d'autres conséquences émotionnelles, comportementales et atteintes à la santé mentale chez les enfants et les adolescents exposés à un événement traumatique ?

• Quelles sont les psychothérapies les plus efficaces ?

• Les psychothérapies sont‐elles plus efficaces que les approches pharmacologiques ou d'autres traitements ?

Quelles études ont été incluses dans cette revue ?

Les auteurs de la revue ont effectué des recherches dans les bases de données jusqu'à mai 2015 pour trouver tous les essais pertinents. Pour être incluses dans la revue, les études devaient être des essais contrôlés randomisés et devaient inclure des enfants et des adolescents exposés à un traumatisme.

Nous avons inclus 51 essais portant sur un total de 6201 participants. Les participants avaient été exposés à des abus sexuels dans 12 essais, à des situations de guerre ou à de la violence dans dix essais, à un traumatisme physique et à des catastrophes naturelles dans six essais et à des violences interpersonnelles dans trois essais. Dans un essai les participants avaient souffert d'une maladie menaçant le pronostic vital ou avaient été victimes d'abus physiques ou de maltraitance. Les participants dans les essais restants ont été exposés à un éventail de traumatismes.

La plupart des essais comparaient une psychothérapie à une intervention contrôle, telle que le traitement habituel, la participation à une liste d'attente ou l'absence de traitement ; d'autres comparaient différentes psychothérapies entre elles.

Un total de 43 études présentaient des critères de jugement évalués au cours du premier mois après la fin du traitement ; 27 études rapportaient des critères de jugement évalués entre un mois et un an, et huit d'entre‐elles ont fourni des données mesurées à un an ou plus après la fin du traitement.

Que disent les preuves présentées dans cette revue ?

Les enfants et les adolescents recevant des psychothérapies étaient moins susceptibles de présenter un diagnostic de TSPT et présentaient moins de symptômes de TSPT jusqu'à un mois après le traitement par rapport à ceux n'ayant reçu aucun traitement, à ceux ayant obtenu un traitement habituel ou à ceux qui étaient sur une liste d'attente. Notre confiance dans ces résultats est limitée car la qualité globale des preuves était faible à très faible. Il n'y avait aucune preuve concernant l'efficacité des psychothérapies au‐delà d'un mois. Il y avait des preuves de qualité modérée indiquant que la thérapie cognitivo‐comportementale (TCC) pourrait être plus efficace pour réduire les symptômes de TSPT par rapport à d'autres psychothérapies au bout d'un mois. Les effets indésirables n'ont pas été rapportés. Il n'y avait aucune étude comparant les psychothérapies à des traitements médicamenteux.

Quelles sont les recommandations pour l'avenir ?

Les chercheurs devraient effectuer des essais de haute qualité afin d'évaluer l'efficacité des psychothérapies pour les enfants et les adolescents exposés à un traumatisme. Ces essais devraient être conçus de manière à s'assurer que les participants et leurs familles ne soient pas conscients du fait qu'ils reçoivent une psychothérapie, en particulier lorsque des mesures sont effectuées par les participants ou leurs parents. En outre, des efforts doivent être effectués afin de garantir des taux élevés de suivi au‐delà d'un mois après la fin du traitement.

Enfin, les études devraient comparer différents types de psychothérapies pour mieux indiquer si les enfants et les adolescents exposés à différents types de traumatismes sont plus ou moins susceptibles de répondre à ces thérapies.

Authors' conclusions

disponible en

Implications for practice

Although we found some evidence for the effectiveness of psychological therapies, particularly CBT, in preventing the onset of PTSD and decreasing PTSD symptoms in children and adolescents for up to a month after treatment, the quality of this evidence was very low to moderate, and effects were not apparent in the longer term. In addition, the level of improvement appears to be considerably lower in children exposed to trauma compared with those diagnosed with PTSD (Gillies 2012), in whom improvement was seen for up to 12 months following therapy.

Implications for research

More evidence is needed to evaluate the effectiveness of psychological therapies longer than one month after treatment. Much more evidence is needed to demonstrate the relative effectiveness of psychological therapies for children and adolescents exposed to trauma.

Future trials should aim to be double‐blind by attempting to ensure that participants and their families are not aware of who is receiving an active intervention. This can be achieved by a two‐factor design whereby two combined therapies are compared with one of those therapies as a control. In addition to achieving more effective blinding of participants and parents, this design is more ethical in that both groups receive treatment. Measures completed by blinded observers such as clinicians, in addition to measures completed by participants or their families, should also be included. Efforts should be made to ensure high rates of follow‐up in the longer term (i.e. longer than one month after therapy). In addition, data from future studies should describe the types of trauma to which children and adolescents are exposed and the time between trauma exposure and therapy. This would be best achieved by making individual participant data available for meta‐analysis.

Summary of findings

Open in table viewer
Summary of findings for the main comparison. Psychological therapies versus wait list, treatment as usual or no treatment for children and adolescents exposed to trauma (short‐term)

Patient or population: children and adolescents exposed to trauma
Setting: three hospitals and fourteen community/outpatient settings (including eight schools, a trauma clinic, child support services, foster care and youth support services) in the US (6), Australia (2), Democratic Republic of Congo (2), Israel (2), the Palestinian territories (2), Bosnia(1), Canada (1), and Indonesia (1).
Intervention: all psychological therapies
Comparison: control (short‐term)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with control (short‐term)

Risk with all psychotherapies

PTSD diagnosis

Study population

OR 0.51
(0.34 to 0.77)

874
(5 studies)

⊕⊝⊝⊝
Very lowa,b,c

367 per 1000

228 per 1000
(165 to 309)

Moderate

345 per 1000

212 per 1000
(152 to 288)

PTSD total symptoms

Mean PTSD total symptoms in the intervention group 0.42 standard deviations undefined fewer (0.61 fewer to 0.24 fewer)

Moderate effect size

2051
(15 studies)

⊕⊕⊝⊝
Lowd,e

*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and relative effect of the intervention (and its 95% CI)
CI: confidence interval; OR: odds ratio; RR: risk ratio

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect but may be substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aParticipants are likely to have been aware of whether they received the active or inactive intervention in all studies, and diagnosis was based on self reported measures in 2 studies
bSignificant difference between the 2 psychological therapies included in this analysis (i.e. CBT and family therapy) (I2 = 69%)
cOnly 3 included studies with a relatively small overall sample number of 352

dParticipants were likely to have been aware of whether they received active or inactive intervention in all but one study, and scores were based on self reported measures in 10 studies

eSubstantial heterogeneity between different types of psychological therapy (I2 = 71%)

Open in table viewer
Summary of findings 2. CBT versus other psychological therapies for children and adolescents exposed to trauma (short‐term)

Patient or population: children and adolescents exposed to trauma
Setting: All seven studies were done in community or outpatient settings including child trauma (2) or psychiatric (2) services, child support services (1), domestic violence service (1) and school (1) in the US (4), Netherlands (2), and Iran (1).
Intervention: CBT
Comparison: other psychological therapies (short‐term)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

Numer of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with other therapies (short‐term)

Risk with CBT

PTSD diagnosis

Study population

OR 0.74
(0.29 to 1.91)

160
(2 studies)

⊕⊝⊝⊝
Very lowa,b

141 per 1000

108 per 1000
(45 to 239)

Moderate

111 per 1000

85 per 1000
(35 to 193)

PTSD total symptoms

Mean PTSD total symptoms in the intervention group 0.24 standard deviations undefined fewer (0.42 fewer to 0.05 fewer)

Small effect size

466
(7 studies)

⊕⊕⊕⊝
Moderatec

*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and relative effect of the intervention (and its 95% CI)
CI: confidence interval; OR: odds ratio; RR: risk ratio

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aParticipants are likely to have been aware of whether they received active or inactive intervention in both studies, and diagnosis was based on self reported measures in both
bOnly 2 included studies with a relatively small overall sample number of 287

cParticipants are likely to have been aware of whether they received active or inactive intervention in all studies, and scores were based on self reported measures in 4 studies

Background

disponible en

Description of the condition

Children and adolescents exposed to trauma are at high risk of post‐traumatic stress disorder (PTSD) and other negative emotional, behavioural and mental health outcomes. Although estimates of the prevalence of PTSD in children and adolescents who have experienced trauma vary, most studies have reported prevalence of 30% to 40% (AACAP 1998; Fletcher 2003; McNally 1996; Saigh 1996), and a meta‐analysis of 34 studies of 2697 children and adolescents exposed to traumatic events (Fletcher 2003) reported an overall prevalence of 36%. The prevalence of PTSD appears to vary with several factors, such as type of trauma, frequency and severity of exposure and time since the traumatic event (Carr 2004; Donnelly 2002; Fletcher 2003; Foy 1996; Yule 2001). Multiple studies have identified co‐morbidities between PTSD and other psychiatric disorders, including depression and anxiety disorders, externalising disorders, substance use and suicidal ideation (AACAP 1998; APA 2000; Donnelly 2002; Perrin 2000).

Characteristic symptoms of PTSD include re‐experiencing the trauma (such as recurrent memories or nightmares), avoiding stimuli associated with the trauma and increased arousal and reactivity (APA 2000; WHO 1990). According to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM‐IV‐TR) criteria for a PTSD diagnosis, symptoms must be present for at least a month and must cause clinically significant distress or impairment in social, occupational or other important areas of function (APA 2000). Types of traumatic events that may cause PTSD include natural and man‐made disasters, war, physical or sexual abuse, violence to self or others, exposure to suicidal acts, serious injury and life‐threatening illness such as cancer or severe burns (AACAP 1998; APA 2000; Parry‐Jones 1995).

Description of the intervention

For children who have been exposed to trauma, psychological therapies are intended to prevent the onset of trauma‐related symptoms or PTSD (Forman‐Hoffman 2013). Although a range of psychological therapies are used with people exposed to trauma (see How the intervention might work), most therapies are based on one or more common elements. These may include psychoeducational elements, which may help traumatised children or adolescents to normalise PTSD reactions; psychodynamic elements, which can help them to process the trauma emotionally and gain a better understanding of its meaning to them; exposure elements, which can desensitise them to trauma‐related memories; cognitive‐behavioural elements, which help them rethink assumptions and reactions to the traumatic event; and coping elements or skills, such as problem solving, safety planning and anxiety management (AACAP 2010; Carr 2004; Robertson 2004; Sones 2011). Inclusion of parents may enhance the effectiveness of these therapies with children and adolescents by improving parental recognition of trauma symptoms and enhancing their ability to help with their child's emotional distress and to manage related behaviour problems (AACAP 2010). Psychological therapies may be targeted to the individual or may be group‐based, and the frequency and duration of treatment may vary widely.

How the intervention might work

Several trauma‐specific and generic psychological therapeutic approaches have been used to prevent negative outcomes among children and adolescents who have undergone trauma. Cognitive‐behavioural therapy (CBT) challenges the distorted, negative thinking patterns associated with the trauma to help people develop more adaptive cognitions and behaviours (Robertson 2004; Sones 2011). Exposure therapy is used to help people overcome symptoms by exposing them to specific or non‐specific cues or memories related to the trauma (Neuner 2004; Robertson 2004). Because the fragmentation and distortion of memories and cognitions associated with trauma are thought to prevent symptom resolution, narrative therapy can be used to help someone reconstruct a consistent narrative about the trauma (Neuner 2004). Therapists work with individuals in psychodynamic psychotherapy to help them develop a better understanding of their responses to the trauma and how it impacts their feelings, behaviours and relationships (AACAP 2010; BluePages 2012; Foa 1997). In eye movement desensitisation and reprocessing (EMDR), the individual focuses on a disturbing image, memory, emotion or cognition associated with the trauma, while the therapist initiates rapid voluntary eye movements (Bryant 2001; Robertson 2004). Other therapies include supportive therapy, whereby counsellors give support, listen to people and help them talk over their problems (BluePages 2012); debriefing, which allows emotional processing or ventilation by encouraging recollection, ventilation and reworking of the traumatic event (Rose 2002); and family therapy, which can reduce psychological symptoms by focusing on improving family communication and functioning (Henken 2007).

Why it is important to do this review

Although a Cochrane review has been conducted to examine the effectiveness of psychological interventions for children and adolescents diagnosed with PTSD (Gillies 2012), no Cochrane reviews have studied available psychological therapies for prevention of PTSD in children and adolescents exposed to trauma. Therefore, we have prepared this Cochrane review to address the remaining need for a systematic review of the effectiveness of psychological therapies for prevention of PTSD and other negative outcomes in children and adolescents who have undergone trauma.

Objectives

disponible en

To assess the effects of psychological therapies in preventing PTSD and associated negative emotional, behavioural and mental health outcomes in children and adolescents who have undergone a traumatic event.

Methods

disponible en

Criteria for considering studies for this review

Types of studies

All relevant randomised and quasi‐randomised controlled trials. Quasi‐randomised studies included studies that used allocation methods with no apparent association with participant characteristics. For example, we could include studies that allocated participants on the basis of the last numeral of the medical identifier number or the last numeral of the date of birth.

All cross‐over trials and cluster‐randomised trials were eligible for inclusion.

Types of participants

Participant characteristics

We included studies of children or adolescents, boys and girls, up to and including 18 years of age, who had been exposed to a traumatic event. Trauma is defined as an event in which the child or adolescent experienced, witnessed or was confronted with an event or events that involved actual or threatened death or serious injury, or a threat to the physical integrity of self or others, and response involved intense fear, helplessness or horror, which in children may be expressed as disorganised or agitated behaviour (APA 2000). Trauma may include natural or man‐made disaster, physical or sexual abuse, war, violence and life‐threatening injury.

The primary criterion of exposure to trauma differentiates this review, which focuses on the effectiveness of psychological therapies in prevention of PTSD, from the previously published review on psychological therapies as treatment for children and adolescents with PTSD (Gillies 2012).

Diagnosis

Although the inclusion criterion for this review was exposure to trauma, participants in some identified studies may have been diagnosed with PTSD or might have had baseline symptom scores that were above validated cut‐off scores for PTSD. Therefore, for this review we included studies if less than 50% of participants in both groups had baseline symptom scores above validated cut‐offs, or were diagnosed with PTSD using validated methods. When 50% or more of participants received a diagnosis of PTSD or had baseline scores above validated cut‐off scores, these were considered treatment studies and included in Gillies 2012 or, if newly identified, will be included in updates of Gillies 2012.

Co‐morbidities

We included studies of participants with any co‐morbidity.

Setting

We placed no restriction on the setting of studies.

Subset data

If children and adolescents were randomised separately, and if data for children or adolescents were reported as a subset of data in a study that included adults, we would have included these data.

Types of interventions

Experimental interventions

  • Major categories of psychological therapies included CBT (including both cognitive and behavioural components), exposure therapy, family therapy, EMDR, narrative therapy, psychodynamic therapy (including play therapy), psychoeducation, immediate post‐trauma interventions such as debriefing and psychological first aid and supportive therapy (including non‐directive counselling). Therapies had to be used primarily with the child or adolescent and could be delivered in any format including individual or group therapies but could also include parents or could have parents attend parallel sessions.

Comparator interventions

  • Control (treatment as usual, waiting list controls or no treatment).

  • Another psychological therapy.

  • Pharmacological therapy.

Types of outcome measures

Reports of the following outcomes were not required for studies to be considered for inclusion in this review. If it was apparent that these outcomes had not been measured (rather than had not been reported) upon review of these studies, we excluded them and provided the reasons for exclusion.

Primary outcomes

1. Diagnosis of post‐traumatic stress disorder determined by accepted clinical diagnostic criteria such as International Classification of Diseases, Revision 10 (ICD‐10), or DSM‐IV‐TR.

2. Symptoms of PTSD measured on scales based on diagnostic criteria such as ICD‐10 or DSM‐IV‐TR with published reliability and validity (e.g. Children's PTSD Inventory) (Saigh 2000).

Secondary outcomes

3. Severity or incidence of anxiety symptoms (e.g. State‐Trait Anxiety Inventory for Children) (Spielberger 1973).

4. Severity or incidence of depressive symptoms (e.g. Children's Depression Inventory) (Kovacs 1992).

5. Severity or incidence of behavioural problems (e.g. Child Behavior Checklist) (Achenbach 1983).

6. Function (e.g. Children's Global Assessment Scale) (Schaffer 1983).

7. Quality of life (e.g. Pediatric Quality of Life Inventory, version 4.0) (Varni 2001).

8. Any adverse events including self harm or suicidal behaviour.

9. Cost.

10. Loss to follow‐up.

Outcome scales

We included outcome data only if the scale or questionnaire was reported to be valid and reliable in a peer‐reviewed journal. If useable data for a particular outcome were collected from different sources (i.e. PTSD symptoms reported by child and parent in Celano 1996, Danielson 2012, Jaberghaderi 2004, Kemp 2010 and Schottelkorb 2012), we used data that showed the highest response rates. If follow‐up was the same for all raters, we used clinician scales in preference because these were based on clinician interview with child and parent, which is considered by expert groups as the most valid form of assessment (AACAP 1998).

Timing of outcome assessment

Data were analysed as short‐term (up to and including one month following completion of therapy), medium‐term (between one month and one year following therapy) and long‐term (one year or longer).

Hierarchy of outcome measures

If two or more sets of data were available for any of these periods, we used the first data set. For example, if follow‐up data were reported at three months and six months, we used data for the three‐month follow‐up period.

Search methods for identification of studies

Cochrane Common Mental Disorders Group's Specialised Register (CCMDCTR)

The Cochrane Common Mental Disorders Group maintains a specialised register of randomized controlled trials, the CCMDCTR. This register contains over 40,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating disorders, self‐harm and other mental disorders within the scope of this Group. The CCMDCTR is a partially studies based register with >50% of reference records tagged to c12,500 individually PICO coded study records. Reports of trials for inclusion in the register are collated from (weekly) generic searches of Medline (1950‐), Embase (1974‐) and PsycINFO (1967‐), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also sourced from international trial registries, drug companies, the hand‐searching of key journals, conference proceedings and other (non‐Cochrane) systematic reviews and meta‐analyses. Details of CCMD's core search strategies (used to identify RCTs) can be found on the Group's website with an example of the core Medline search displayed in Appendix 1.

Electronic searches

1. Cochrane Specialised Register

CCDMDCTR ‐ Studies Register

We searched the studies register (to 29‐May‐2015) using the following terms.

Diagnosis = ("post‐traumatic stress disorders" or "acute stress disorder" or stress)
and
Age‐Group = (child or adolescent)
and
Intervention = (counsel* or *therapy or intervention or training or *education).

CCDMDCTR ‐ References Register

We searched the References Register (to 29‐May‐2015) using a more sensitive set of free‐text terms to identify additional untagged/uncoded references.

Title/Abstract/Keywords = (PTSD or “post trauma*” or post‐trauma* or posttrauma* or trauma* or stress) and (adolesc* or preadolesc* or pre‐adolesc* or boy* or girl* or child* or infant* or juvenil* or minors or school* or pediatri* or paediatri* or pubescen* or puberty or student* or teen* or young or youth* or school* or high‐school or “high school” or college or undergrad*).

2. Interntional Trial Registers

We searched ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) to 29‐May‐2015

Searching other resources

We checked reference lists of relevant studies and reviews for additional references to potentially relevant studies. We included non‐English language studies.

Data collection and analysis

Selection of studies

Two review authors checked the results of database searches to exclude references that clearly were not relevant to the review. These review authors then assessed titles and/or abstracts of the remaining studies, as well as studies identified by other methods, to determine eligibility for the review. We resolved disagreements regarding selection of studies through consensus or, if necessary, by consultation with a third member of the review team. When doubt remained, we obtained and reviewed the full‐text article. When further clarification by study authors was needed for a decision, we made all reasonable attempts to contact them.

Data extraction and management

Members of the review team developed and piloted a data extraction form. Two members of the review group independently extracted methodological and outcome data from each study. Each pair then compared results to identify differences. If identified, we resolved differences by consensus or by referral to a third member of the review team. When further clarification or missing data were needed from study authors, we made all reasonable attempts to contact them.

Extracted data included information about participants, including inclusion criteria, exclusion criteria and number, age, ethnicity and gender; details of study setting and information on trauma exposure and symptoms; information on interventions, including major components of each therapy as described by study authors, whether treatment was manualised and length, frequency and format of sessions; the professional background of therapists, any intervention training received and supervision or fidelity; and outcomes, including which measures were used, who rated them and when they were measured. These study characteristics are reported in the Characteristics of included studies tables, with details provided by study authors.

The three main planned comparisons were:

  1. psychological therapies versus control (wait list, treatment as usual, no treatment);

  2. psychological therapies versus other psychological therapies; and

  3. psychological therapies versus pharmacological therapies.

We organised data under the following categories of psychological therapies.

  1. Cognitive‐behavioural therapy (CBT).

  2. Eye movement desensitisation and reprocessing (EMDR).

  3. Exposure‐based therapy.

  4. Family therapy.

  5. Narrative therapy.

  6. Post‐trauma interventions (including debriefing and psychological first aid).

  7. Psychodynamic psychotherapy (including play therapy).

  8. Psychoeducation.

  9. Supportive therapy (including non‐directive counselling).

Assessment of risk of bias in included studies

We independently assessed trials as having 'low', 'high' or 'unclear' risk of bias according to the following quality criteria (Higgins 2008).

  1. Adequate sequence generation (selection bias).

  2. Allocation concealment (selection bias).

  3. Blinding of participants (performance bias).

  4. Blinding of outcome assessment (detection bias).

  5. Incomplete outcome data (attrition bias).

  6. Free of selective reporting (selective reporting).

  7. Free of any other bias.

When disagreement arose about whether a trial fulfilled particular quality criteria, we resolved differences by consensus or by referral to a third member of the review team.

As little is available to inform levels of attrition that are acceptable, it is difficult to make an objective judgement about the level of attrition bias; therefore, we considered two factors: percentage loss to follow‐up and use of imputed data; the latter was treated as a positive factor against attrition bias. Therefore, we considered attrition of less than 5% as associated with low risk of bias, whether completer or imputed data were reported. If attrition was between 5% and 15%, it was considered to involved unclear risk of bias if completer data were reported, and low risk if imputed data were reported. if attrition was greater than 15% up to 30%, completer data were considered to show high risk, and imputed data as unclear risk; if attrition was greater than 30%, both were considered to show high risk of attrition bias. If loss to follow‐up was greater than 50% in either group, we did not include study data. We investigated potential differences between groups in loss to follow‐up by performing meta‐analysis.

Measures of treatment effect

Dichotomous data

For binary outcomes, we calculated the odds ratio (OR) and the 95% confidence interval (95% CI) by using a random‐effects model.

Continuous data

We calculated the standardised mean difference (SMD) and the 95% CI of continuous outcomes by using a random‐effects model. SMDs were used to pool continuous outcomes when different measures were used. However, to ensure consistency of reporting in this review, we used SMDs throughout.

To calculate SMDs, we needed means and standard deviations (SDs). If SDs were not reported, we calculated them from reported measures of variance such as standard errors or 95% CIs, if possible.

Skewed data

As a meta‐analysis is based on assumptions of normality, we checked all continuous data for skew before inclusion. For a scale that starts from zero, we considered a standard deviation that is more than half the mean to show strong evidence of a skewed distribution (Higgins 2008). Therefore, if the standard deviation was greater than the mean for both groups, we did not include these data in a meta‐analysis and reported them separately.

Unit of analysis issues

Cross‐over trials

We identified no cross‐over trials. If we had found these, we would have used only first interval data, as the likelihood of a carryover effect is high when psychological therapy is provided.

Cluster‐randomised trials

We intended to correct data for cluster‐randomised trials for paired analysis; however, as intracluster correlations were not available for these trials, we conducted sensitivity analyses to identify whether inclusion of these trials had affected meta‐analytical findings.

Studies with multiple treatment groups

If a study included multiple treatment arms that described different comparisons, we would have analysed these separately. For example, if a three‐armed trial incorporated narrative therapy, supportive therapy and a control treatment arm, we would use these data in comparisons of narrative therapy versus control, supportive therapy versus control and narrative therapy versus supportive therapy. However, no studies in this review reported multiple treatment arms.

Dealing with missing data

We used intention‐to‐treat data and imputed values such as last observation carried forward when these were reported. We conducted sensitivity analyses to test for effects of loss to follow‐up on the stability of results.

Assessment of heterogeneity

We used a Mantel‐Haenszel Chi2 statistic test and I2 analysis to test for heterogeneity.

Based on the recommendations of Higgins 2008 (9.5.2), we interpreted heterogeneity by using the following values of I2.

  • 0% to 40%: might not be important.

  • 30% to 60%: may represent moderate heterogeneity.

  • 50% to 90%: may represent substantial heterogeneity.

  • 75% to 100%: shows considerable heterogeneity.

Assessment of reporting biases

We entered primary outcome data from all included studies into a funnel plot (trial effect against trial size) to investigate the possibility of publication bias (Egger 1997).

Data synthesis

We collected data for all follow‐up periods as long as loss to follow‐up did not exceed 50% for either group. We analysed data as short‐term (up to and including one month following completion of therapy), medium‐term (between one month and one year following therapy) and long‐term (one year or longer). If two or more more sets of useable data were provided for any of these periods, we used the first data set.

When studies reported data for more than one group (e.g. Tol 2012, which reported data for boys and girls separately), we calculated pooled means and standard deviations and used them in the meta‐analysis.

In meta‐analyses of psychological therapies versus control, we used studies that compared an added psychological therapy versus another psychological therapy (i.e. Berliner 1996, which compared exposure plus supportive therapy versus supportive therapy only, and Deblinger 2011, which compared narrative therapy plus CBT versus CBT) when the additional psychological therapy was considered the control intervention. We investigated effects of psychological therapies as controls in the sensitivity analysis for active versus inactive controls (Analysis 11.1; Analysis 11.2).

When cluster‐randomised trials were identified, we would have made appropriate corrections for the cluster design if appropriate data had been reported, and these data were incorporated into the meta‐analyses. However, data that could be used to make these corrections were not reported.

Subgroup analysis and investigation of heterogeneity

We explored whether clinical differences between studies may have resulted in different estimates of effectiveness through subgroup analyses. These included

  • type of therapy: CBT, debriefing, EMDR, family therapy, narrative therapy, psychoeducation, supportive therapy;

  • type of trauma: sexual abuse, maltreatment, physical trauma, life‐threatening illness, interpersonal violence, community violence or war, natural disaster. For studies that included participants who had experienced a range of traumas, if most experienced a particular type of trauma (e.g. Berkowitz 2011, in which most participants experienced physical trauma), we analysed them under this category;

  • therapy mode: individual versus group, child versus mother, child therapy;

  • type of control: active control (e.g. treatment as usual, which included elements of psychological therapy, or compared a particular psychological therapy as an adjunct to another therapy) or inactive control (e.g. no treatment, wait list, craft group); and

  • inclusion of symptoms as part of the inclusion criteria compared with symptom levels not defined.

Sensitivity analysis

We conducted sensitivity analysis for loss to follow‐up using best‐case and worst‐case analyses of the primary binary outcome ‐ improvement. For the best‐case analysis, we considered all participants lost to follow‐up to have improved, and for the worst‐case analysis, we considered participants lost to follow‐up to be not improved. Studies that did not report loss to follow‐up could not be included in this analysis.

We also carried out sensitivity analyses based on whether studies were rated as having low, unclear or high risk of selection, performance, detection and attrition bias. In addition, we assessed whether including data from cluster‐randomised trials had an effect on the analysis.

Therefore, sensitivity analyses were performed as follows.

  • Best‐case versus worst‐case analysis.

  • Selection bias: low versus unclear versus high risk.

  • Performance bias: low versus unclear versus high risk.

  • Detection bias: low versus unclear versus high risk.

  • Attrition bias: low versus unclear versus high risk.

  • Cluster versus individually randomised trials.

'Summary of findings' tables

We created 'Summary of findings' tables for primary outcomes, PTSD and symptoms for all psychological therapies compared with control, and for CBT compared with other psychological therapies in the short‐term. We used the five GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of evidence for each outcome, and to draw conclusions about quality of evidence within the text of the review.

Results

Description of studies

Results of the search

From 172 study records, we identified 116 studies for review (see Figure 1 for Search flow diagram), included 51 studies (88 citations) with a total of 6201 participants (see Characteristics of included studies) and excluded 46 studies (59 records) (Characteristics of excluded studies). We have not yet assessed 14 studies, three because they require translation and the remainder because data were not available at the time of writing the review (Characteristics of studies awaiting classification); we also identified five ongoing studies (Characteristics of ongoing studies).


PRISMA study flow diagram.

PRISMA study flow diagram.

Included studies

See Characteristics of included studies.

Ten included studies were cluster‐randomised controlled trials. Berger 2009, Berger 2012, Berliner 1996, Qouta 2012 and Shechtman 2010 randomised classes; Tol 2008, Tol 2012 and Tol 2014 randomised schools; Barron 2013 randomised counsellors; and Overbeek 2013 randomised children and family therapists. All other included studies randomised participants to interventions.

Settings

Most (27) included trials were done in the United States (Baker 1985; Berkowitz 2011; Berliner 1996; Carbonell 1999; Carrion 2013; Celano 1996; Chapman 2001; Chemtob 2002; Cohen 1996; Cohen 2005; Cohen 2011; Danielson 2012; Deblinger 1996; Deblinger 2001; Deblinger 2011; Dominguez 2001; Glodich 2000; Kazak 2004; Lieberman 2005; Pace 2013; Raider 2008; Salloum 2008; Salloum 2012; Shirk 2014; Stein 2003; Taussig 2010); three in the the Democratic Republic of Congo (O'Callaghan 2013; O'Callaghan 2014; McMullen 2013); two each were carried out in Australia (Cox 2010; Kemp 2010),Israel (Berger 2012; Shechtman 2010), the Netherlands (Diehle 2014; Overbeek 2013), Palestine (Barron 2013; Qouta 2012), Sri Lanka (Berger 2009; Tol 2012) and the UK (Stallard 2006; Trowell 2002). One study each was done in Bosnia (Layne 2008), Burundi (Tol 2014), Canada (Farkas 2010), Indonesia (Tol 2008), Iran (Jaberghaderi 2004), Jordan (Damra 2014), Peru (Church 2012), Sierra Leone (Betancourt 2014) and Switzerland (Zehnder 2010).

Participants

Included studies consisted of 6201 participants, and the number in each trial ranged from 16 (Church 2012; Jaberghaderi 2004) to 482 (Qouta 2012).

Ages of participants ranged from two to 24 years. Twenty trials included children only (Berliner 1996; Carbonell 1999; Celano 1996; Chemtob 2002; Damra 2014; Deblinger 1996; Deblinger 2001; Deblinger 2011; Jaberghaderi 2004; Kemp 2010; Overbeek 2013; Qouta 2012; Salloum 2008; Salloum 2012; Schottelkorb 2012; Stein 2003; Taussig 2010; Tol 2008; Tol 2012; Tol 2014), and 18 trials included both children and adolescents (Barron 2013; Berger 2009; Berkowitz 2011; Carrion 2013; Chapman 2001; Church 2012; Cohen 2005; Cohen 2011; Cox 2010; Diehle 2014; Dominguez 2001; Kazak 2004; O'Callaghan 2013; O'Callaghan 2014; Shechtman 2010; Stallard 2006; Trowell 2002; Zehnder 2010). Nine trials included only adolescents (Baker 1985; Berger 2012; Danielson 2012; Farkas 2010; Glodich 2000; Layne 2008; Pace 2013; Raider 2008; Shirk 2014) and two preschool children only (Cohen 1996; Lieberman 2005). Betancourt 2014 included adolescents and young adults, but because the mean age of participants was 18 years, we included this study.

In 12 trials, the targeted trauma was sexual abuse (Baker 1985; Berliner 1996; Celano 1996; Cohen 1996; Cohen 2005; Danielson 2012; Deblinger 1996; Deblinger 2001; Deblinger 2011; Dominguez 2001; Jaberghaderi 2004; Trowell 2002). Participants were exposed to war or community violence in ten trials (Betancourt 2014; Glodich 2000; Layne 2008; O'Callaghan 2014; McMullen 2013; Qouta 2012; Stein 2003; Tol 2008; Tol 2012; Tol 2014); physical trauma (Berkowitz 2011; Chapman 2001; Cox 2010; Kemp 2010; Stallard 2006; Zehnder 2010) and natural disaster in six trials each (Barron 2013; Berger 2009; Berger 2012; Chemtob 2002; Salloum 2008; Salloum 2012); and interpersonal violence in three (Cohen 2011; Lieberman 2005; Overbeek 2013); and had suffered a life‐threatening illness (Kazak 2004), had been physically abused (Damra 2014) or were maltreated (Taussig 2010) in one trial each. Participants in the remaining trials were exposed to a range of traumas (Carbonell 1999; Carrion 2013; Church 2012; Diehle 2014; Farkas 2010; O'Callaghan 2013; Pace 2013; Raider 2008; Schottelkorb 2012; Shechtman 2010; Shirk 2014). Participants were frequently exposed to more than one type of trauma in most trials.

Fifteen studies included participants on the basis of some measure of post‐trauma symptoms or reported baseline symptoms. To be included, participants needed a score of at least 12 on the Post‐Traumatic Stress Disorder Index (PTSD‐I) in Chapman 2001, a score of at least 7 on the Weekly Behaviour Report in Cohen 1996, at least one post‐traumatic symptom in Berkowitz 2011, significant symptoms in Cohen 2005, at least five symptoms with one from each cluster in Cohen 2011 and Deblinger 2011, clinical symptoms of PTSD in Damra 2014, at least three symptoms including at least one re‐experiencing or avoidance symptom in Deblinger 1996 and full or partial PTSD (although 5/32 had no diagnosis of PTSD) in Diehle 2014, or they had to be one of 10 students with the highest Children's Revised Impact of Events Scale (CRIES) scores in each class in Barron 2013. Mean baseline Post‐Traumatic Stress Disorder Reaction Index (PTSD‐RI) item scores were 0.68 in the therapies group and 0.77 in the control group in Betancourt 2014, PTSD‐RI total scores ranged from 22.70 to 25.80 in Carrion 2013, and mean Impact of Events Scale (IES) score was 34.2 in Church 2012. A ‘chart diagnosis’ was recorded for 81% of participants in Berliner 1996, and 88% met self reported Diagnostic and Statistical Manual, Fourth Edition (DSM‐IV) criteria for PTSD in Chemtob 2002.

Interventions

Most included trials compared a psychological therapy versus control (i.e. wait list, treatment as usual or no treatment). The psychological therapy was categorised predominantly as CBT in 17 trials (Barron 2013; Berger 2009; Berger 2012; Betancourt 2014; Carrion 2013; Damra 2014; Deblinger 1996; Layne 2008; O'Callaghan 2013; McMullen 2013; Pace 2013; Qouta 2012; Shirk 2014; Stein 2003; Tol 2008; Tol 2012; Tol 2014); as family therapy in four trials (Danielson 2012; Kazak 2004; Lieberman 2005; Raider 2008); as debriefing (Chapman 2001; Stallard 2006; Zehnder 2010) and psychoeducation/skills training (Cox 2010; Glodich 2000; O'Callaghan 2014) in three trials each; as narrative therapy (Carbonell 1999; Salloum 2012), supportive therapy (Shechtman 2010; Taussig 2010) and EMDR (Farkas 2010; Kemp 2010) in two trials each; and as exposure (Church 2012) or CBT plus narrative therapy (O'Callaghan 2013) in one trial each. Although these trials were broadly categorised under these therapies, several psychotherapeutic elements were common to a range of therapies. In particular, psychoeducation and coping skills were common to most interventions.

Among trials that compared one form of therapy versus another, eight compared CBT with supportive therapy (Berkowitz 2011; Celano 1996; Cohen 1996; Cohen 2005; Cohen 2011; Deblinger 2001; Dominguez 2001; Overbeek 2013), two compared CBT with EMDR (Diehle 2014; Jaberghaderi 2004) and one compared CBT with psychodynamic therapy (Schottelkorb 2012). Berliner 1996 compared exposure plus supportive therapy with supportive therapy only, and Deblinger 2011 compared narrative therapy plus CBT with CBT alone.

Five trials compared different models of delivery for psychological therapies. Four trials compared individual delivery of a psychological therapy versus group delivery of the same therapy (Baker 1985; Chemtob 2002; Salloum 2008; Trowell 2002), and Deblinger 1996 compared CBT for children only versus CBT for both mothers and children.

Three trials used a single intervention session (Chapman 2001; Stallard 2006; Zehnder 2010), and the remaining trials used between four and 40 therapy sessions but most commonly 10 to 15 sessions of 45 minutes to two hours, usually on a weekly basis. Interventions were delivered in a group setting in 20 trials (Barron 2013; Berger 2009; Berger 2012; Berliner 1996; Betancourt 2014; Carbonell 1999; Deblinger 2001; Glodich 2000; Kazak 2004; Layne 2008; O'Callaghan 2013; O'Callaghan 2014; Overbeek 2013; Pace 2013; Qouta 2012; Shechtman 2010; Stein 2003; Tol 2008; Tol 2012; Tol 2014).

Eleven trials were based on individual sessions with children (Carrion 2013; Chapman 2001; Church 2012; Diehle 2014; Dominguez 2001; Farkas 2010; Jaberghaderi 2004; Kemp 2010; Schottelkorb 2012; Shirk 2014; Stallard 2006), eight used a combination of individual and group delivery modes (Baker 1985; Chemtob 2002; McMullen 2013; Raider 2008; Salloum 2008; Salloum 2012; Taussig 2010; Trowell 2002) and one used a Web‐based intervention (Cox 2010). All other therapies involved parents or caregivers. Most of these were individual sessions that included parents for at least part of the therapy (Berkowitz 2011; Celano 1996; Cohen 1996; Deblinger 2011; Lieberman 2005; Zehnder 2010) or run in parallel with child and parent (Cohen 2005; Damra 2014) or consisted of both joint and parallel sessions (Cohen 2011; Danielson 2012; Deblinger 1996). Overbeek 2013 ran parallel group sessions for children and parents, and Qouta 2012 ran groups that included both.

Outcomes

Children and adolescents were diagnosed with PTSD on the basis of the Anxiety Disorder Interview Schedule for DSM‐IV (ADIS‐P; Diehle 2014), the Clinician Administered PostTraumatic Stress Disorder Scale for Children (Stallard 2006), the Diagnostic Interview Schedule for Children (Farkas 2010), the Semi Structured Interview for Diagnostic Classification (Lieberman 2005) and the Kiddie Schedule for Affective Disorders and Schizophrenia for school‐aged children ‐ Epidemiologic version (K‐SADS‐E; Deblinger 1996). They were also considered to have PTSD if they had a score of 3 or higher on one item of the University of California, Los Angeles (UCLA) PTSD Index (Berger 2009; Berger 2012), a total score of 38 or higher on the UCLA PTSD Index (Salloum 2008; Salloum 2012) or a score of 17 or higher on the intrusion/avoidance subscales of the Children's Revised Impact of Events Scale (CRIES)‐13 (Barron 2013).

The most frequently used measure for PTSD symptoms was the UCLA PTSD Index (Berger 2009; Betancourt 2014; Carrion 2013; Chapman 2001; Cohen 2011; Danielson 2012; Kazak 2004; Layne 2008; McMullen 2013; O'Callaghan 2013; Salloum 2008; Salloum 2012; Schottelkorb 2012) or the earlier version, the Child Post‐Traumatic Stress Reaction Index (Kemp 2010; Shechtman 2010), followed by the Trauma Symptom Checklist for Children (Berkowitz 2011; Cohen 2005; Cox 2010; Farkas 2010; Overbeek 2013; Raider 2008; Taussig 2010) or the Trauma Symptom Checklist for Young Children (Overbeek 2013); the Impact of Events Scale ‐ Revised (Church 2012; Cox 2010; Glodich 2000; Kazak 2004) or the earlier Impact of Traumatic Events Scale (Dominguez 2001; Kemp 2010; Stallard 2006); the K‐SADS‐E (Deblinger 1996; Deblinger 2001) and the K‐SADS ‐ Present and Lifetime (PL) version (Deblinger 2011; Shirk 2014; Trowell 2002); and the Child PTSD Symptoms Scale (Stein 2003; Tol 2008; Tol 2012; Tol 2014). Trauma symptoms were also measured by the CRIES‐13 (Barron 2013; Celano 1996; Diehle 2014; Qouta 2012) or revised version (CRIES‐8; O'Callaghan 2013); the Clinician Administered PTSD Scale (CAPS‐CA; Diehle 2014; Zehnder 2010); the Child Report of Post‐Traumatic Symptoms and the Parent Report of Post‐Traumatic Symptoms (Jaberghaderi 2004; Schottelkorb 2012); the Kauai Recovery Index (Chemtob 2002); Post‐Traumatic Stress Symptoms in Children (PTSS‐C; Damra 2014); and the Semi Structured Interview for Diagnostic Classification 0 to 3 (Lieberman 2005).

For depression, most used the Children's Depression Inventory (Berliner 1996; Carrion 2013; Cohen 2005; Cohen 2011; Damra 2014; Danielson 2012; Deblinger 1996; Deblinger 2011; Dominguez 2001; Overbeek 2013; Stein 2003; Zehnder 2010), followed by the Depression Self Rating Scale (Barron 2013; Layne 2008; Qouta 2012; Stallard 2006; Tol 2008; Tol 2012; Tol 2014). Other trials used the Beck Depression Inventory (Berger 2009; Shirk 2014); the Birleson Depression Inventory (Stallard 2006); the Children’s Depression Scale (Kemp 2010); the Institute for Personality and Ability Testing Depression Scale (Baker 1985); the Mood and Feelings Questionnaire (Salloum 2008; Salloum 2012); Orvaschel's PTSD scale (Trowell 2002); the Trauma Symptom Checklist for Children‐A (TSCC‐A; Cox 2010; Farkas 2010); and the Quick Inventory of Depressive Symptomatology (Pace 2013). Depression was diagnosed by a score of 29 or higher on the Mood and Feelings Questionnaire in Salloum 2008 and Salloum 2012 or on the K‐SADS‐PL (Shirk 2014).

The scales most frequently used to measure anxiety were the Revised Children's Manifest Anxiety Scale (Berliner 1996; Carrion 2013; Kazak 2004; Shechtman 2010; Stallard 2006), the State‐Trait Anxiety Inventory for Children (Cohen 2005; Deblinger 1996; Kemp 2010); the Screen for Child Anxiety Related Emotional Disorders (SCARED; Berger 2012; Cohen 2011; Tol 2008; Tol 2012); and the Trauma Symptom Checklist for Children (Berkowitz 2011; Cox 2010; Farkas 2010). Anxiety was also measured with the Institute for Personality and Ability Testing Anxiety Scale (Baker 1985); the Revised Child Anxiety and Depression Scale (Diehle 2014); the Multidimensional Anxiety Scale for Children (Deblinger 2011); and the State‐Trait Anxiety Inventory (Pace 2013).

Most trials measured behaviour with the Child Behavior Checklist (Berliner 1996; Celano 1996; Cohen 1996; Cohen 2005; Deblinger 1996; Deblinger 2001; Deblinger 2011; Farkas 2010; Kemp 2010; Lieberman 2005; Overbeek 2013; Salloum 2012; Shirk 2014; Zehnder 2010). Other measures of behaviour included the Strengths and Difficulties Questionnaire (SDQ; Barron 2013; Diehle 2014; Stallard 2006; Tol 2012); the Behavioral Assessment System for Children (BASC‐2; Danielson 2012); the Children’s Aggression Scale for Parents (Tol 2008); internalising and externalising items from the Oxford Measure of Psychosocial Adjustment (Betancourt 2014); the Teacher’s Report Form (Overbeek 2013); the Teacher‐Child Rating Scale (Stein 2003); the Youth Self‐Report (Glodich 2000; Raider 2008); and the African Youth Psychosocial Assessment (McMullen 2013; O'Callaghan 2013; O'Callaghan 2014).

Psychosocial function was measured by the Children's Global Assessment Scale (Celano 1996); the Kiddie Global Assessment Scale (Trowell 2002); the Pediatric Symptom Checklist (Stein 2003); and the Word Health Organization (WHO) Disability Adjustment Scale (Betancourt 2014). Functional impairment was measured by the Child Diagnostic Interview Schedule in Berger 2012 and by a scale developed by study authors in Tol 2008, Tol 2012 and Tol 2014.

Quality of life was measured by the Life Satisfaction Survey in Taussig 2010.

Cost in Great Britain pounds was reported in Trowell 2002.

Most studies (42) reported outcomes recorded within the first month after treatment; 27 studies reported outcomes from one month up to a year, and eight reported data for a year or longer after completion of treatment.

Data that could not be added to the meta‐analysis

Data from six studies could not be used because loss to follow‐up was greater than 50% for at least one group. Data included post‐treatment function in Celano 1996, PTSD symptoms and behaviour at three and 12 months in Deblinger 1996, symptoms of PTSD and depression at four months in Layne 2008 and all post‐treatment outcomes in Carrion 2013. Other than behaviour post treatment in Cohen 1996, loss to follow‐up was greater than 50% in the supportive therapy group at six and 12 months in Cohen 1996 and for all intervals in Cohen 2005.

Data from three studies could not be used in meta‐analyses because the required data were not reported and could not be calculated or obtained from study authors. Sample numbers were not clear in Chemtob 2002, and outcomes were reported as the intercept and the slope of a growth curve in Dominguez 2001; no variance was given in Chapman 2001.

Data from two studies could not be used in meta‐analyses because they showed substantial evidence of skew. Standard deviations were greater than mean PTSD scores for all groups in Deblinger 2001 and greater than all PTSD subscores in Cox 2010.

Data from three studies (Church 2012; Damra 2014; McMullen 2013) are reported separately (Table 1; Table 2; Table 3) because the effect size in all studies was several times higher than the overall estimate and contributed from 45% to 90% heterogeneity if they were added to meta‐analyses.

Open in table viewer
Table 1. Data from Church 2012

Outcome

Group

n

Mean

SD

PTSD symptoms

One month

Exposure therapy

8

3.38

2.60

Control

8

31.38

3.84

Avoidance

One month

Exposure therapy

8

2.88

2.62

Control

8

20.25

2.38

Intrusion

One month

Exposure therapy

8

0.50

0.50

Control

8

11.13

2.93

Open in table viewer
Table 2. Data from Damra 2014

Outcome

Group

n

Mean

SD

PTSD symptoms

Post therapy

TF‐CBT

9

13.00

1.12

Control

9

24.20

1.54

PTSD symptoms

4 months

TF‐CBT

9

11.88

1.96

Control

9

23.98

1.47

Open in table viewer
Table 3. Data from McMullen 2013

Outcome

Group

n

Mean

SD

PTSD symptoms

Post therapy

TF‐CBT

24

10.6

4.5

Control

24

34.8

11.6

Conduct Problems

Post therapy

TF‐CBT

24

0.7

0.9

Control

24

7.1

7.0

Excluded studies

See Characteristics of excluded studies.

We excluded 46 studies, but six of these (Catani 2009; Cohen 2004; Ertl 2011; King 2000; Ruf 2010; Schauer 2008) were included in the Cochrane review on psychological therapies for treatment of PTSD in children and adolescents (Gillies 2012), and seven will be reviewed in the update (Chen 2014; Jacob 2014; Jensen 2014; Murray 2015; Rosner 2014; Ruf 2012; Soltanifar 2012).

We obtained full copies of the remaining 33 studies, as it was not clear from the available title or abstract whether they would meet the inclusion criteria. We excluded most because allocation was not randomised (Burke 1988; Ehntholt 2005; Gellman 2001; Goenjian 1997; Jeffres 2004; Kenardy 2008; Krueger 2013; Pfeffer 2002; Shooshtary 2008; Thabet 2005; Wang 2011; Wolmer 2011a; Wolmer 2011b) or study participants were not screened for exposure to trauma (Berger 2007; Bolton 2007; Cooley‐Strickland 2011; Gelkopf 2009; Hardin 2002; Jordans 2010; Rubin 2001; Wang 2011). Less than 50% of participants in the intervention group were randomised in Scheeringa 2011, the average age of participants was 19 years in Schaal 2009, no comparison group was included in Goenjian 1997 and Shelby 1995, the intervention was not a psychological therapy in Kassam‐Adams 2011 and Phipps 2012 and was used with mothers only in Dybdahl 2001 and follow‐up was only 10% in Saxe 2012 and 25% in the control group in Pfeffer 2002. Data were not reported and could not be obtained for Ensink 2004 and McWhirter 2011, and no data for the control group could be obtained for Kataoka 2003. Lyshak‐Stelzer 2007 was an interim publication of a trial that had already reported very high loss to follow‐up.

Studies awaiting classification

Fourteen studies are awaiting assessment (see Characteristics of studies awaiting classification). We have not yet assessed three randomised controlled trials (RCTs) as translations of these findings are not yet available (Mahmoudi‐Gharaei 2006; Narimani 2013,Shen 2012). The remainder have not been assessed as data were not available at the time of writing this review.

In contrast to our included studies, which were mostly done in the United States, the studies awaiting assessment were conducted in African countries including Burundi (Crombach 2012), Northern Uganda (Elbert 2009); and South Africa (Elbert 2013), Australia (Ooi 2010), China (Shen 2012; Zang 2013), Iran (Mahmoudi‐Gharaei 2006; Narimani 2013), Sweden (Hultmann 2012), Switzerland (Kramer 2014), and the UK (Jessiman 2013), with three in the United States (Kassam‐Adams 2016; Rowe 2013; Ruggiero 2015).

Participants had been affected by natural disasters (Mahmoudi‐Gharaei 2006; Rowe 2013; Shen 2012; Zang 2013); by war (Elbert 2009; Ooi 2010); by interpersonal abuse (Jessiman 2013; Hultmann 2012); by physical illness or injury (Kramer 2014;Ruggiero 2015;Kassam‐Adams 2016); unspecified traumatic events (Elbert 2009; Narimani 2013); or were violent offenders who had been exposed to traumatic stress (Elbert 2013).

Controls were compared to CBT (Hultmann 2012; Ooi 2010; Mahmoudi‐Gharaei 2006; Narimani 2013); guided narrative technique (Crombach 2012; Elbert 2009; Elbert 2013; Zang 2013); 'Letting the Future in' for children affected by sexual abuse (Jessiman 2013); a debriefing, psychoeducation and coping intervention (Kramer 2014); and expressive group counselling (Shen 2012). Controls were also compared to two web‐based interventions, ‘Coping Coach’ (Kassam‐Adams 2016) and ‘Bounce Back’ (Ruggiero 2015). The other studies compared different psychological therapies: Elbert 2013 compared FORNET, a narrative exposure therapy, to CBT; and Rowe 2013 compared group‐based CBT to family therapy. Mahmoudi‐Gharaei 2006 compared CBT to CBT plus art and sport interventions, and an art and sport intervention alone.

Ongoing studies

We identified five ongoing RCTs (see Characteristics of ongoing studies). These are being conducted in Kenya or Tanzania (Dorsey 2012), Australia (Sansom‐Daly 2012), the Netherlands (Roos 2013) and the United States (Belcher 2009; Toth 2011).

Participants had one or both parents die (Dorsey 2012); were exposed to neglect (Belcher 2009) or maltreatment (Toth 2011); had recently completed cancer treatment (Sansom‐Daly 2012); or had been exposed to a single traumatic event (Roos 2013).

Interventions compared with controls in ongoing trials include trauma‐focused CBT (Dorsey 2012) and family‐based therapy (Belcher 2009). Three ongoing trials are comparing different psychological therapies: 'Recapture Life’, an online group‐based CBT, is being compared with online supportive therapy (Sansom‐Daly 2012); EMDR to cognitive‐behavioural writing therapy (Roos 2013); and interpersonal therapy to enhanced care (Toth 2011).

Risk of bias in included studies

For graphical representations of the overall risk of bias in included trials, see Figure 2 and Figure 3.


Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.


Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Allocation

Barron 2013 was considered to have high risk of selection bias because even though counsellors were randomised, they then identified participant classes. The generation of a randomisation sequence was described and was considered to lead to low risk of bias in 25 trials (Baker 1985; Berger 2009; Berger 2012; Berkowitz 2011; Berliner 1996; Betancourt 2014; Chemtob 2002; Cohen 1996; Cohen 2005; Cohen 2011; Cox 2010; Danielson 2012; Deblinger 2001; Diehle 2014; Glodich 2000; Jaberghaderi 2004; McMullen 2013; O'Callaghan 2013; O'Callaghan 2014; Overbeek 2013; Pace 2013; Salloum 2012; Schottelkorb 2012; Stallard 2006; Stein 2003) and to unclear risk in the remainder.

Barron 2013 was also considered at high risk because of allocation concealment based on selection of participant classes. Eight included trials (Berliner 1996; Cohen 2011; Diehle 2014; O'Callaghan 2013; O'Callaghan 2014; Overbeek 2013; Stallard 2006; Stein 2003) were considered to have low risk. Allocation concealment was not described in the remaining 42 trials, which therefore were rated as having unclear risk.

Blinding

Participants were likely to be aware of whether they had been assigned to an intervention group or a control group in 32 trials (Barron 2013; Berger 2009; Berger 2012; Betancourt 2014; Carbonell 1999; Carrion 2013; Chapman 2001; Chemtob 2002; Church 2012; Cox 2010; Damra 2014; Danielson 2012; Deblinger 1996; Farkas 2010; Glodich 2000; Kazak 2004; Kemp 2010; Lieberman 2005; McMullen 2013; O'Callaghan 2013; O'Callaghan 2014; Pace 2013; Qouta 2012; Raider 2008; Shechtman 2010; Stallard 2006; Stein 2003; Taussig 2010; Tol 2008; Tol 2012; Tol 2014; Zehnder 2010); therefore, these were rated as having high risk of performance bias. Participants in both groups received therapy in Diehle 2014, Overbeek 2013 and Shirk 2014, and these studies were rated as having low risk. All other trials were rated as having unclear risk of performance bias.

Primary outcomes were self reported in most studies (30) in which participants were probably aware of whether they received an intervention; these studies were rated as having high risk of detection bias (Barron 2013; Berger 2009; Berger 2012; Betancourt 2014; Carbonell 1999; Carrion 2013; Chapman 2001; Chemtob 2002; Church 2012; Cox 2010; Damra 2014; Danielson 2012; Deblinger 1996; Farkas 2010; Glodich 2000; Kazak 2004; Kemp 2010; McMullen 2013; O'Callaghan 2013; O'Callaghan 2014; Pace 2013; Qouta 2012; Raider 2008; Shechtman 2010; Stein 2003; Taussig 2010; Tol 2008; Tol 2012; Tol 2014; Zehnder 2010). Trials were rated as having low risk of bias when blinded assessment of primary outcomes was described (Lieberman 2005; Shirk 2014; Stallard 2006), and when studies that used self reported primary measures provided therapy to both groups (Diehle 2014; Overbeek 2013). Risk was rated as unclear in the remaining 15 studies.

Incomplete outcome data

Risk of attrition bias was low in 10 studies. Berger 2009, Berger 2012, Church 2012 and Damra 2014 reported no apparent loss to follow‐up, and loss to follow‐up was less than 5% in Tol 2012 and Zehnder 2010. Loss to follow‐up in Betancourt 2014, Danielson 2012, O'Callaghan 2014 and Tol 2008 was between 5% and 15%, but imputed values were used to account for missing data.

Other trials that reported completer data were rated as having unclear risk of bias if loss to follow‐up was between 5% and 15% (Barron 2013; Glodich 2000; Jaberghaderi 2004; Kemp 2010; O'Callaghan 2013; Salloum 2012; Stein 2003; Taussig 2010). If loss to follow‐up was between 15% and 25% but imputed values were used to account for missing data, the risk was considered unclear (Berkowitz 2011; Cohen 2005; Cohen 2011; Cox 2010; Deblinger 2011; Diehle 2014; Overbeek 2013; Shirk 2014; Trowell 2002). In addition, if loss to follow‐up was not reported (Baker 1985; Chapman 2001; Chemtob 2002; Tol 2014), studies were rated as having unclear risk.

We considered 18 trials to have high risk of attrition bias because incomplete outcome data were reported and attrition rates were greater than 15% (i.e. Berliner 1996; Carbonell 1999; Celano 1996; Cohen 1996; Deblinger 1996; Deblinger 2001; Dominguez 2001; Farkas 2010; Layne 2008; Lieberman 2005; McMullen 2013; Pace 2013; Qouta 2012; Raider 2008; Salloum 2008; Schottelkorb 2012; Shechtman 2010; Stallard 2006). We also rated Kazak 2004 as having high risk of attrition bias even though imputed results were reported, because loss to follow‐up was differentially higher in the intervention group than in the control group (38% versus 7%). Studies that used imputed data but reported loss to follow‐up greater than 30% were also considered to have high risk of bias (Berliner 1996; Cohen 2005; Cohen 2011; Cox 2010; Diehle 2014; Farkas 2010).

Selective reporting

The primary outcome of PTSD symptoms were not reported in four trials (Berger 2009; Chapman 2001; Diehle 2014; Shirk 2014), which therefore were rated as having high risk of reporting bias. Studies that did not report secondary outcomes such as Trowell 2002, which did not report depression, anxiety and hyperarousal; Stallard 2006 did not report parent SDQ scores; and O'Callaghan 2014, which did not report function, were rated as having unclear risk of bias. It was not clear whether all outcomes were reported in Barron 2013, Church 2012, Damra 2014, Danielson 2012, Deblinger 1996, Glodich 2000, Lieberman 2005, O'Callaghan 2013, Overbeek 2013, Salloum 2008, Tol 2012 and Tol 2014, which therefore were rated as having unclear risk of bias. All other trials appeared to report all outcomes and were rated as having low risk of reporting bias.

Other potential sources of bias

We rated eight studies as having high risk of other bias because they reported a baseline imbalance in the primary outcome of a PTSD diagnosis, post‐trauma symptoms or exposure to trauma. The baseline diagnosis of PTSD in the usual care group was twice as high as in the intervention group (61% versus 30%) in Shirk 2014, and was 53% higher in Stallard 2006 (35.5% versus 23.2%). Baseline symptom scores were significantly higher in the wait list group in Kemp 2010 (34.6 versus 22.3) and 10% higher in Betancourt 2014. Wait list participants in Tol 2008 were twice as likely to be displaced (75%) compared with those in the intervention group (37%). More participants in the intervention group had a baseline diagnosis of PTSD in Farkas 2010 (37% versus 19%) and clinically significant symptoms in Qouta 2012 (64% versus 43%). Baseline PTSD symptoms were also higher in the treatment group in both Farkas 2010 (6.4 versus 3.7) and Qouta 2012 (32.8 versus 27.8). Participants who had undergone sexual abuse accounted for 19% of those in the intervention group compared with only 4% in the wait list group in Pace 2013, and neglect was 52.0% in the wait list group and 29.6% in the intervention group.

We considered three studies to have unclear risk of other potential bias because they were less likely to have a direct effect on primary outcomes. Participants in the intervention group in Taussig 2010 were more likely to have undergone physical abuse and maternal neglect and to have a mother with a criminal history, although their scores for IQ, coping and social support were higher. Baseline conduct scores were approximately 17% higher in the intervention group in O'Callaghan 2014. In Shirk 2014, therapists in the intervention group had a total of 38 years of clinical experience compared with seven years among those in the usual care group, and intervention therapists received 'more targeted and frequent' case supervision. Raider 2008 referred to five participants who dropped out in the early sessions of group therapy but did not appear to be included among the 23 randomised participants. In Glodich 2000, data from a student who joined the treatment group after randomisation were included. Church 2012 and Damra 2014 were also considered to have unclear risk of additional bias because potential differences between groups were not investigated.

We considered all other trials to have low risk because no other bias was apparent.

Effects of interventions

See: Summary of findings for the main comparison Psychological therapies versus wait list, treatment as usual or no treatment for children and adolescents exposed to trauma (short‐term); Summary of findings 2 CBT versus other psychological therapies for children and adolescents exposed to trauma (short‐term)

Outcomes collected over these trials included diagnosis of PTSD, PTSD symptoms (total scores and subscores for arousal, avoidance and intrusion), anxiety (total, state and trait), depression, behaviour (total, internalising and externalising), function, quality of life, cost and loss to follow‐up.

Comparison 1. All psychological therapies versus controls

Primary outcomes
1. Diagnosis of PTSD

Across all trials that compared a psychological therapy versus a control, a significantly smaller proportion of children and adolescents who received therapy interventions had been diagnosed with PTSD at the end of the study in the short term (odds ratio (OR) 0.51, 95% confidence interval (CI) 0.34 to 0.77; 874 participants; five studies; I2 = 22%; number needed to treat for an additional beneficial outcome (NNTB) 9, 95% CI 6 to 20; Analysis 1.1), but not in the medium (OR 0.66, 95% CI 0.26 to 1.69; 742 participants; four studies; I2 = 70%; Analysis 2.1) or long term (OR 0.56, 95% CI 0.09 to 3.62; 64 participants; one study; Analysis 3.1).

2. PTSD symptoms

Scores for PTSD symptoms were significantly lower in the psychological therapy group in the short term (standardised mean difference (SMD) ‐0.42, 95% CI ‐0.61 to ‐0.24; 2051 participants; 17 studies; high heterogeneity at I2 = 71%; Analysis 1.2) than in the medium (SMD ‐0.17, 95% CI ‐0.38 to 0.05; 2337 participants; 13 studies; I2 = 83%; Analysis 2.2) or long term (SMD 0.17, 95% CI ‐0.28 to 0.62; 141 participants; two studies; I2 = 44%; Analysis 3.2). Church 2012 and Damra 2014 also reported significant improvement in overall trauma symptoms, but because these differences were approximately 20 times greater than in the other included studies, data were included in the meta‐analysis but did not contribute to the overall estimate.

Investigators reported no differences between psychological therapy and control for any of the PTSD domains of avoidance, hyperarousal and intrusion in the short (Analysis 1.3; Analysis 1.4; Analysis 1.5) or medium term (Analysis 2.3; Analysis 2.4; Analysis 2.5). Long‐term PTSD domain data were not reported.

Secondary outcomes
3. Anxiety

Scores for anxiety symptoms were not significantly different in the psychological therapy groups compared with the control groups in the short term (SMD ‐0.13, 95% CI ‐0.26 to 0.00; 959 participants; seven studies; I2 = 3%; Analysis 1.6), medium term (SMD ‐0.10, 95% CI ‐0.20 to 0.00; 1470 participants; seven studies; I2 = 0%; Analysis 2.6) or long term (SMD ‐0.12, 95% CI ‐0.41 to 0.18; 176 participants; two studies; I2 = 0%; Analysis 3.3). State anxiety was significantly less in the therapy groups in the short (SMD ‐0.64, 95% CI ‐1.12 to ‐0.16; 70 participants; two studies; I2 = 0%; Analysis 1.7) and medium term (SMD ‐0.71, 95% CI ‐1.31 to ‐0.12; 46 participants; one study; Analysis 2.7). Trait anxiety was not different in the short term (Analysis 1.8) but was significantly less in the medium term (SMD ‐0.45, 95% CI ‐0.85 to ‐0.05; 101 participants; two studies; I2 = 0%; Analysis 2.8). State anxiety and trait anxiety were not reported in the long term.

4. Depression

Scores for depression symptoms were not significantly lower in the psychological therapy group in the short term (SMD ‐0.13, 95% CI ‐0.30 to 0.04; 1569 participants; 13 studies; I2 = 52%; Analysis 1.9), medium term (SMD ‐0.07, 95% CI ‐0.22 to 0.07; 2191 participants; 13 studies; I2 = 55%; Analysis 2.9) or long term (SMD ‐0.12, 95% CI ‐0.41 to 0.18; 176 participants; two studies; I2 = 0%; Analysis 3.4).

5. Behaviour

Total behaviour scores were not significantly lower in the psychological therapy group in the short (SMD ‐0.04, 95% CI ‐0.51 to 0.42; 166 participants; three studies; I2 = 51%; Analysis 1.10), medium (SMD ‐0.20, 95% CI ‐0.43 to 0.04; 281 participants; three studies; I2 = 0%; Analysis 2.10) or long term (SMD 0.39, 95% CI ‐0.07 to 0.85; 77 participants; one study; Analysis 3.5).

Scores for internalising behaviour were not different in the short (SMD ‐0.04, 95% CI ‐0.20 to 0.13; 719 participants; 10 studies; I2 = 16%; Analysis 1.11), medium (SMD 0.01, 95% CI ‐0.25 to 0.28; 291 participants; four studies; I2 = 16%; Analysis 2.11) or long term (SMD 0.04, 95% CI ‐0.51 to 0.59; 141 participants; two studies; I2 = 63%; Analysis 3.6). Researchers reported no differences between groups in externalising behaviour in the short (SMD ‐0.10, 95% CI ‐0.33 to 0.14; 1174 participants; 12 studies; I2 = 68%; Analysis 1.12), medium (SMD ‐0.11, 95% CI ‐0.38 to 0.17; 206 participants; two studies; I2 = 0%; Analysis 2.12) or long term (SMD 0.28, 95% CI ‐0.05 to 0.60; 298 participants; three studies; I2 = 46%; Analysis 3.7).

6. Functional impairment

Function was significantly improved in the group receiving psychological therapy in the short (SMD ‐0.41, 95% CI ‐0.59 to ‐0.24; 557 participants; two studies; I2 = 0%; Analysis 1.13) and medium term (SMD ‐0.46, 95% CI ‐0.88 to ‐0.05; three studies; I2 = 88%; Analysis 2.13). No study reported long‐term function scores.

7. Quality of life

Investigators reported no differences between groups in quality of life measures in the short (SMD 0.03, 95% CI ‐0.30 to 0.36; 144 participants; one study; Analysis 1.14) and medium term (SMD 0.13, 95% CI ‐0.19 to 0.46; 144 participants; one study; Analysis 2.14). Long‐term quality of life was not reported.

8. Adverse events

Researchers provided no adverse events data.

9. Cost

Researchers provided no cost data.

10. Loss to follow‐up

Among all trials that compared a psychological therapy versus a control, investigators reported no differences in the proportions of children and adolescents lost to follow‐up in the short term (risk ratio (RR) 0.98, 95% CI 0.69 to 1.39; 3872 participants; 26 studies; I2 = 59%; Analysis 1.15), medium term (OR 1.00, 95% CI 0.82 to 1.21; 3663 participants; 20 studies; I2 = 71%; Analysis 2.15) or long term (SMD 0.28, 95% CI ‐0.05 to 0.60; 298 participants; three studies; I2 = 46%; Analysis 3.7).

Subgroup analyses of psychological therapies
Primary outcomes

Diagnosis of PTSD

We noted no significant differences between the therapy subgroups of CBT, EMDR and family therapy in PTSD diagnosis in the short (Analysis 1.1), medium (Analysis 2.1) or long term (Analysis 3.1).

PTSD symptoms

In the short term, we observed significant differences between therapy subgroups in effects on symptoms of PTSD (P value < 0.0001; Analysis 1.2). With CBT (SMD ‐0.37, 95% CI ‐0.55 to ‐0.19; 1329 participants; seven studies; I2 = 55%), family therapy (SMD ‐0.53, 95% CI ‐0.94 to ‐0.12; 95 participants; two studies; I2 = 0%) and CBT plus narrative therapy (SMD ‐1.96, 95% CI ‐2.63 to ‐1.29; 52 participants; one study), all symptom scores were improved compared with control, and we noted no differences in scores when EMDR, psychoeducation and narrative, supportive and exposure therapies were compared with controls. We found no differences between therapy subgroups in the medium term (Analysis 2.2) and observed that none of the therapies (CBT, debriefing, family therapy, narrative therapy, psychoeducation and supportive therapy) were significantly different from controls. We observed no differences between the two single trials that compared exposure therapy versus control and narrative therapy versus control in the long term (Analysis 2.3), and no subgroup differences for any of the PTSD domains of avoidance (Analysis 1.3; Analysis 2.3), hyperarousal (Analysis 1.4; Analysis 2.4) and intrusion (Analysis 1.5; Analysis 2.5) in the short or medium term; we found no long‐term data.

Secondary outcomes

Anxiety

We found no significant differences between therapy groups when comparing anxiety scores with those of a control group in the short (Analysis 1.6), medium (Analysis 2.6) or long term (Analysis 3.3), nor did we note differences between therapy groups in state (Analysis 1.7; Analysis 2.7) or trait anxiety (Analysis 1.8; Analysis 2.8), which was reported in the short and medium term.

Depression

We found no significant differences between therapy subgroups for the outcome of depression in the short (Analysis 1.9), medium (Analysis 2.9) or long term (Analysis 3.4).

Behaviour

Although we noted no differences between therapy subgroups for total (Analysis 1.10; Analysis 2.10) or internalising behaviour (Analysis 1.11; Analysis 2.11; Analysis 3.6) scores, we observed a significant difference for externalising behaviour scores in the short term (P value = 0.004; Analysis 1.12). Externalising behaviours were significantly greater in the therapy groups in the single trials that compared exposure therapy versus control (SMD 0.49, 95% CI 0.03 to 0.95; 77 participants; Analysis 1.12) and fewer in the trial that compared CBT plus narrative therapy versus control (SMD ‐1.06, 95% CI ‐1.64 to ‐0.47; 52 participants; Analysis 1.12).

Function

Function was reported only in trials that compared CBT versus control in the short (Analysis 1.13) and medium term (Analysis 2.13).

Quality of life

Only one trial of supportive therapy compared with control reported quality of life in the short (Analysis 1.14) and medium term (Analysis 2.14).

Adverse events

No data were reported.

Cost

No data were reported.

Loss to follow‐up

We found no differences between therapy subgroups in loss to follow‐up in the short (Analysis 1.15), medium (Analysis 2.15) or long term (Analysis 3.8).

Comparison 2. Psychological therapies versus other psychological therapies

We were able to compare CBT with other pooled therapies for the primary outcomes only. We report these results below; thereafter, we report the results subgrouped by comparator.

CBT versus other psychological therapies
Primary outcomes

1. Diagnosis of PTSD

CBT was found to be no more or less effective than EMDR and supportive therapy in reducing diagnosis of PTSD in the short term (OR 0.74, 95% CI 0.29 to 1.91; 2 studies, 160 participants; Analysis 4.1). The quality of the evidence was very low.

2. PTSD symptoms

For reduction of PTSD symptoms in the short term, there was a small effect favouring CBT over EMDR, play therapy and supportive therapies (SMD ‐0.24, 95% CI ‐0.42 to ‐0.05, 7 studies, 466 participants; Analysis 4.2). The quality of the evidence was moderate. 

CBT versus EMDR

One study compared CBT versus EMDR, and all reported outcomes were short term.

Primary outcomes

1. Diagnosis of PTSD

No data were reported.

2. PTSD symptoms

Scores for PTSD symptoms were not significantly different when CBT was compared with EMDR (SMD 0.06, 95% CI ‐0.44 to 0.56; 62 participants; two studies; I2 = 0%; Analysis 4.2).

Secondary outcomes

3. Anxiety

No data were reported.

4. Depression

No data were reported.

5. Behaviour

Total behaviour scores were not significantly different between groups (SMD ‐0.44, 95% CI ‐1.50 to 0.63; 14 participants; one study; Analysis 4.8).

6. Function

No data were reported.

7. Quality of life

No data were reported.

8. Adverse events

No data were reported.

9. Cost

No data were reported.

10. Loss to follow‐up

We observed no differences in loss to follow‐up at the end of the study (OR 0.76, 95% CI 0.23 to 2.52; 64 participants; two studies; I2 = 0%; Analysis 4.12).

CBT versus psychodynamic therapy

The one study that compared CBT versus psychodynamic therapy reported only short‐term outcomes.

Primary outcomes

1. Diagnosis of PTSD

No data were reported.

2. PTSD symptoms

PTSD symptom scores were not significantly different between groups (SMD 0.21, 95% CI ‐0.56 to 0.98; 26 participants; Analysis 5.1).

Secondary outcomes

3. Anxiety

No data were reported.

4. Depression

No data were reported.

5. Behaviour

No data were reported.

6. Function

No data were reported.

7. Quality of life

No data were reported.

8. Adverse events

No data were reported.

9. Cost

No data were reported.

10. Loss to follow‐up

We noted no differences in the proportions of children and adolescents lost to follow‐up at the end of the study (OR 0.08, 95% CI 0.00 to 1.56; 31 participants; Analysis 4.12).

CBT versus supportive therapy

Four trials compared CBT versus supportive therapy.

Primary outcomes

1. Diagnosis of PTSD

We found no differences in the proportions of children and adolescents diagnosed with PTSD in the short term (OR 0.71, 95% CI 0.26 to 1.95; 124 participants; one study; Analysis 4.1) when CBT was compared with supportive therapy. The diagnosis of PTSD was not reported in the medium or long term.

2. PTSD symptoms

Scores for PTSD symptoms were significantly lower in the CBT group in the short term (SMD ‐0.32, 95% CI ‐0.53 to ‐0.12; 378 participants; four studies; I2 = 0%; Analysis 4.2) but not in the medium term (SMD ‐0.16, 95% CI ‐0.43 to 0.11; 223 participants; two studies; I2 = 0%; Analysis 5.1).

Short‐term scores for PTSD avoidance (SMD ‐0.40, 95% CI ‐0.76 to ‐0.05; 124 participants; Analysis 4.3) and hyperarousal (SMD ‐0.52, 95% CI ‐0.87 to ‐0.16; 124 participants; Analysis 4.4) were also significantly lower in the CBT group, although we found no differences in intrusion (Analysis 4.5).

Secondary outcomes

3. Anxiety

Anxiety symptoms were significantly lower in the CBT group in the short (SMD ‐0.48, 95% CI ‐0.74 to ‐0.22; 230 participants; two studies; I2 = 0%) but not the medium term (Analysis 4.6).

4. Depression

We found no differences in depression symptoms in the short or medium term (Analysis 4.7).

5. Behaviour

We noted no differences between CBT and supportive therapy groups in total behaviour scores (Analysis 4.8) nor in scores for internalising (Analysis 4.9) or externalising behaviour (Analysis 4.10) at any interval.

6. Function

Function was reported by only one trial in the short term. We found no differences between groups (Analysis 4.11).

7. Quality of life

No data were reported.

8. Adverse events

No data were reported.

9. Cost

No data were reported.

10. Loss to follow‐up

We noted no differences between trials that compared CBT versus supportive therapy in short‐, medium‐ or long‐term loss to follow‐up (Analysis 4.12).

Comparison 3. Psychological therapies versus pharmacological therapies

We identified no trials that compared psychological therapies versus pharmacological therapies.

Subgroup analyses

Group versus individual therapy

Three trials compared delivery of psychological therapies in group and individual modes.

No data were reported for diagnosis of PTSD.

Total PTSD symptom scores were not different when group therapy was compared with individual therapy (Analysis 7.1). These scores were reported in the short term only.

Child versus child and parent therapy

Deblinger 1996 reported data for CBT therapy for children only and data for CBT for children and mothers.

No data were reported for diagnosis of PTSD.

We did not find any difference in symptoms of PTSD when CBT for children was compared to CBT for children and mothers (Analysis 8.1).

Type of trauma

We compared types of trauma including sexual abuse, maltreatment, physical trauma, life‐threatening illness, domestic violence, community violence and war and natural disaster in subgroup analyses.

Effects of psychological therapies on PTSD diagnosis were significantly different when participants exposed to different types of trauma were compared (P value = 0.007; Analysis 9.1). Intervention effects were significantly better compared with those of controls in children and adolescents exposed to community violence (OR 0.59, 95% CI 0.43 to 0.80; 769 participants; three studies; I2 = 0%), interpersonal violence (OR 0.11, 95% CI 0.02 to 0.56; 65 participants; one study) and natural disaster (OR 0.16, 95% CI 0.06 to 0.45; 166 participants; one study), but not in participants who had undergone physical trauma.

Effects on PTSD symptom scores were also significantly different between subgroups who had undergone different types of trauma (P value < 0.00001; Analysis 9.2). Scores were significantly improved for children and adolescents who had undergone sexual abuse (SMD ‐0.67, 95% CI ‐1.18 to ‐0.16; 76 participants; two studies; I2 = 16%) or were exposed to interpersonal violence (SMD ‐0.61, 95% CI ‐1.11 to ‐0.11; 65 participants; one study), natural disaster (SMD ‐1.27, 95% CI ‐1.60 to ‐0.94; 166 participants; one study) or community violence (SMD ‐0.24, 95% CI ‐0.41 to ‐0.06; 2170 participants; eight studies; I2 = 73%), although the latter subgroup was highly heterogeneous (I2 = 73%). We noted no differences between therapy and control groups among children and adolescents who had been maltreated or had undergone physical trauma or life‐threatening illness.

Types of control

We performed a subgroup analysis of active controls (e.g. treatment as usual, which included elements of psychological therapy, or psychological therapy as control, which is used in combination with another therapy in the intervention group) versus an inactive control (e.g. no treatment, wait list, craft group). We found no differences for diagnosis of PTSD (Analysis 11.1) or PTSD symptom scores (Analysis 11.2) when comparing active and inactive control subgroups.

Symptomatic inclusion criteria

We compared studies that included symptoms of PTSD or anxiety as well as exposure to trauma as the inclusion criteria versus studies in which symptoms were not part of the inclusion criteria. We found no significant differences between these subgroups for outcomes of PTSD diagnosis (Analysis 10.1) or symptoms (Analysis 10.2).

Sensitivity analyses

We performed all sensitivity analyses for the primary outcomes of a diagnosis of PTSD and symptoms of PTSD when a psychological therapy was compared with control.

Best‐case/Worst‐case analysis

We found no significant differences between best‐case and worst‐case analyses (Analysis 12.1).

Selection bias

For the outcome of PTSD diagnosis, we found no significant differences between the four trials rated as having low risk of selection bias compared with the single trials rated as having unclear and high risk of bias (Analysis 17.1). We noted no differences between low and unclear risk trials for PTSD symptoms (Analysis 17.2). We rated no trials reporting PTSD symptoms as having high risk of selection bias.

Performance bias

We found no significant differences in the diagnosis of PTSD when we compared the one trial rated as having unclear risk of performance bias versus the five trials rated as having high risk (Analysis 14.1). However, we noted significant differences between subgroups for symptoms of PTSD (one trial with unclear risk versus 17 trials with high risk; P value = 0.02; Analysis 14.2). We rated no trials as having low risk of performance bias.

Detection bias

We found no significant differences between trials rated as having low, unclear or high risk of detection bias for the diagnosis of PTSD (Analysis 15.1) or for symptoms of PTSD (Analysis 15.2).

Attrition bias

We noted significant differences between trials rated as having low, unclear and high risk of attrition bias for the diagnosis of PTSD (Analysis 16.1); however, both low‐ and high‐risk studies resulted in a significant reduction in the diagnosis or PTSD. We found no differences between studies rated as having low, unclear or high risk of attrition bias for symptoms of PTSD (Analysis 16.2).

Cluster‐randomised versus individually randomised trials

We found no significant differences between cluster‐randomised and individually randomised trials for the outcomes of PTSD diagnosis (Analysis 13.1) and symptoms (Analysis 13.2).

Assessment of reporting bias

We created a funnel plot for the primary outcome of PTSD symptoms using data provided by the 15 trials reporting these data in the short term (Figure 4). We noted no asymmetry in the funnel plot.


Funnel plot of comparison: 1 All psychotherapies versus control (short‐term), outcome: 1.2 PTSD total symptoms.

Funnel plot of comparison: 1 All psychotherapies versus control (short‐term), outcome: 1.2 PTSD total symptoms.

Discussion

disponible en

Summary of main results

The likelihood of being diagnosed with post‐traumatic stress disorder (PTSD) and PTSD symptoms were significantly reduced in children and adolescents who received a psychological therapy compared to those who received treatment as usual, no treatment, or were on a wait list for up to a month following treatment. The GRADE quality of evidence for PTSD symptoms was rated low because participants probably were aware of whether they received the intervention and because high levels of heterogeneity between studies (see summary of findings Table for the main comparison). The evidence for diagnosis of PTSD was further limited by small study and participant numbers and therefore rated as very low (see summary of findings Table for the main comparison). The effects of psychological therapies were not apparent over the longer term.

Cognitive‐behavioural therapy (CBT) was found to be no more or less effective than eye movement desensitisation and reprocessing (EMDR) and supportive therapy in reducing diagnosis of PTSD in the short term, although there was evidence favouring CBT over EMDR, play therapy and supportive therapies in reducing symptoms of PTSD for up to a month after treatment. The GRADE quality of evidence for the role of CBT in preventing PTSD diagnosis was rated very low because of lack of blinding and small sample and study numbers. Evidence for the greater effectiveness of CBT in decreasing symptoms of PTSD was rated moderate quality (see summary of findings Table 2).

We did not identify any studies that compared pharmacological therapies to psychological therapies.

Overall completeness and applicability of evidence

Evidence indicates that psychological therapies were effective in preventing the development of PTSD and related symptoms across a range of psychotherapeutic approaches in the short term. Although evidence for the effectiveness of CBT was better, apparent lack of effect with other therapies may be due to lack of data.

Significant benefit from psychological therapies was evident only for up to one month following completion of treatment. Data were insufficient to permit conclusions about the effects of psychological therapies lasting longer than a month after therapy. However, lack of long‐term effects may be due in part to the small number of studies reporting data past one month and the lower rates of follow‐up for those that did so.

Difficulty is associated with conclusions about the applicability of evidence across different types of trauma, as significant differences between trials of children and adolescents with different types of trauma were reported, and generally only one study reported results for each type of trauma.

Although we noted differences in inclusion criteria in that some studies specifically included symptoms (although not a full diagnosis) of PTSD, we found no apparent differences in findings between these studies and those that did not require a predefined level of symptoms as part of the inclusion criteria.

We had intended to include only studies of children and adolescents who had been exposed to trauma within the previous year; however, time since trauma was not an inclusion criterion for any included study, and time since trauma was rarely reported. Therefore, time since trauma may also account for heterogeneity across studies.

Although evidence suggests that psychological therapies were effective in preventing the onset of PTSD and PTSD symptoms in the short term, the quality of studies comparing psychological therapies versus control was relatively low. Few studies compared psychological therapies versus other psychological therapies, and none compared psychological therapies versus pharmacological therapies or other treatments.

Quality of the evidence

Overall, risk of allocation, detection and attrition bias in included trials was unclear because inadequate details were provided by study authors to permit a judgement. Most trials were considered to have high risk of performance bias, and most were considered to have low risk of reporting bias. Marked heterogeneity was evident in several analyses. We conducted several exploratory analyses to identify sources of heterogeneity and noted differences between types of therapy and types of trauma; additional data are needed before conclusions can be drawn about the effectiveness of different therapies and the types of trauma for which they are effective. We identified no differences between trials that used active and inactive controls, but the inactive control subgroup itself was highly heterogeneous. Although we found significant differences between trials rated as having low and unclear risk of selection bias, we noted only one trial determined to have low risk and none determined to have high risk. Performance bias due to the predominance of child‐ or parent‐rated measures may have resulted in an overestimation of effects, but these findings are based on limited data. Although we found differences between risk categories in bias due to attrition, we did not note this effect with symptoms of PTSD. We found no evidence of publication bias when preparing this review. When effects of psychological therapies were apparent, GRADE ratings of the quality of evidence were very low to moderate as the result of study limitations of non‐blinded outcome measurement, lack of consistency across studies in effect size and imprecision due to small numbers of included studies and relatively small sample sizes.

Potential biases in the review process

Data generated from these included trials had some limitations. Most trials were very small, often including fewer than 100 participants and in some cases fewer than 20. Therefore, negative findings with many of these analyses may well be due to lack of power. In addition, most trials reported only short‐term outcomes. Another limitation was that large portions of the continuous data reported in these trials were skewed, and this limited the useability of data.

We used a large range of tools to measure continuous outcomes in this review (more than 20 for PTSD), making integration and interpretation of data difficult. As in the narrative review by Forman‐Hoffman 2013 of interventions for children exposed to non‐relational traumatic events, trials did not replicate interventions, short‐term interventions were reported and most were self reported outcomes.

Agreements and disagreements with other studies or reviews

Findings of this review are in line with those of Cochrane reviews that found good evidence for the effectiveness of CBT in the treatment of adults with PTSD (Bisson 2013) and acute traumatic stress symptoms (Roberts 2010) and in the prevention of adverse consequences of child sexual abuse (MacDonald 2012). In addition, a systematic review by Leenarts 2013 concluded that CBT yielded the best evidence of effectiveness among psychological therapies for children who had been maltreated, and Kramer 2011 concluded from a meta‐analysis of psychological interventions within one month following trauma that interventions should include psychoeducation, coping skills and exposure.

PRISMA study flow diagram.
Figuras y tablas -
Figure 1

PRISMA study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Funnel plot of comparison: 1 All psychotherapies versus control (short‐term), outcome: 1.2 PTSD total symptoms.
Figuras y tablas -
Figure 4

Funnel plot of comparison: 1 All psychotherapies versus control (short‐term), outcome: 1.2 PTSD total symptoms.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 1.1

Comparison 1 All psychotherapies versus control (short‐term), Outcome 1 PTSD diagnosis.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 1.2

Comparison 1 All psychotherapies versus control (short‐term), Outcome 2 PTSD total symptoms.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 3 PTSD avoidance.
Figuras y tablas -
Analysis 1.3

Comparison 1 All psychotherapies versus control (short‐term), Outcome 3 PTSD avoidance.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 4 PTSD hyperarousal.
Figuras y tablas -
Analysis 1.4

Comparison 1 All psychotherapies versus control (short‐term), Outcome 4 PTSD hyperarousal.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 5 PTSD intrusion.
Figuras y tablas -
Analysis 1.5

Comparison 1 All psychotherapies versus control (short‐term), Outcome 5 PTSD intrusion.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 6 Anxiety total symptoms.
Figuras y tablas -
Analysis 1.6

Comparison 1 All psychotherapies versus control (short‐term), Outcome 6 Anxiety total symptoms.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 7 Anxiety ‐ state.
Figuras y tablas -
Analysis 1.7

Comparison 1 All psychotherapies versus control (short‐term), Outcome 7 Anxiety ‐ state.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 8 Anxiety ‐ trait.
Figuras y tablas -
Analysis 1.8

Comparison 1 All psychotherapies versus control (short‐term), Outcome 8 Anxiety ‐ trait.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 9 Depression.
Figuras y tablas -
Analysis 1.9

Comparison 1 All psychotherapies versus control (short‐term), Outcome 9 Depression.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 10 Behaviour ‐ total.
Figuras y tablas -
Analysis 1.10

Comparison 1 All psychotherapies versus control (short‐term), Outcome 10 Behaviour ‐ total.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 11 Behaviour ‐ internalising.
Figuras y tablas -
Analysis 1.11

Comparison 1 All psychotherapies versus control (short‐term), Outcome 11 Behaviour ‐ internalising.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 12 Behaviour ‐ externalising.
Figuras y tablas -
Analysis 1.12

Comparison 1 All psychotherapies versus control (short‐term), Outcome 12 Behaviour ‐ externalising.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 13 Functional impairment.
Figuras y tablas -
Analysis 1.13

Comparison 1 All psychotherapies versus control (short‐term), Outcome 13 Functional impairment.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 14 Quality of life.
Figuras y tablas -
Analysis 1.14

Comparison 1 All psychotherapies versus control (short‐term), Outcome 14 Quality of life.

Comparison 1 All psychotherapies versus control (short‐term), Outcome 15 Loss to follow‐up.
Figuras y tablas -
Analysis 1.15

Comparison 1 All psychotherapies versus control (short‐term), Outcome 15 Loss to follow‐up.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 2.1

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 1 PTSD diagnosis.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 2.2

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 2 PTSD total symptoms.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 3 PTSD ‐ avoidance.
Figuras y tablas -
Analysis 2.3

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 3 PTSD ‐ avoidance.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 4 PTSD ‐ hyperarousal.
Figuras y tablas -
Analysis 2.4

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 4 PTSD ‐ hyperarousal.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 5 PTSD ‐ intrusion.
Figuras y tablas -
Analysis 2.5

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 5 PTSD ‐ intrusion.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 6 Anxiety total symptoms.
Figuras y tablas -
Analysis 2.6

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 6 Anxiety total symptoms.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 7 Anxiety ‐ state.
Figuras y tablas -
Analysis 2.7

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 7 Anxiety ‐ state.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 8 Anxiety ‐ trait.
Figuras y tablas -
Analysis 2.8

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 8 Anxiety ‐ trait.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 9 Depression.
Figuras y tablas -
Analysis 2.9

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 9 Depression.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 10 Behaviour ‐ total.
Figuras y tablas -
Analysis 2.10

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 10 Behaviour ‐ total.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 11 Behaviour ‐ internalising.
Figuras y tablas -
Analysis 2.11

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 11 Behaviour ‐ internalising.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 12 Behaviour ‐ externalising.
Figuras y tablas -
Analysis 2.12

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 12 Behaviour ‐ externalising.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 13 Function.
Figuras y tablas -
Analysis 2.13

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 13 Function.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 14 Quality of life.
Figuras y tablas -
Analysis 2.14

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 14 Quality of life.

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 15 Loss to follow‐up.
Figuras y tablas -
Analysis 2.15

Comparison 2 All psychotherapies versus control (medium‐term), Outcome 15 Loss to follow‐up.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 3.1

Comparison 3 All psychotherapies versus control (long‐term), Outcome 1 PTSD diagnosis.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 3.2

Comparison 3 All psychotherapies versus control (long‐term), Outcome 2 PTSD total symptoms.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 3 Anxiety.
Figuras y tablas -
Analysis 3.3

Comparison 3 All psychotherapies versus control (long‐term), Outcome 3 Anxiety.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 4 Depression.
Figuras y tablas -
Analysis 3.4

Comparison 3 All psychotherapies versus control (long‐term), Outcome 4 Depression.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 5 Behaviour ‐ total.
Figuras y tablas -
Analysis 3.5

Comparison 3 All psychotherapies versus control (long‐term), Outcome 5 Behaviour ‐ total.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 6 Behaviour ‐ internalising.
Figuras y tablas -
Analysis 3.6

Comparison 3 All psychotherapies versus control (long‐term), Outcome 6 Behaviour ‐ internalising.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 7 Behaviour ‐ externalising.
Figuras y tablas -
Analysis 3.7

Comparison 3 All psychotherapies versus control (long‐term), Outcome 7 Behaviour ‐ externalising.

Comparison 3 All psychotherapies versus control (long‐term), Outcome 8 Loss to follow‐up.
Figuras y tablas -
Analysis 3.8

Comparison 3 All psychotherapies versus control (long‐term), Outcome 8 Loss to follow‐up.

Comparison 4 CBT versus other therapies (short‐term), Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 4.1

Comparison 4 CBT versus other therapies (short‐term), Outcome 1 PTSD diagnosis.

Comparison 4 CBT versus other therapies (short‐term), Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 4.2

Comparison 4 CBT versus other therapies (short‐term), Outcome 2 PTSD total symptoms.

Comparison 4 CBT versus other therapies (short‐term), Outcome 3 PTSD avoidance.
Figuras y tablas -
Analysis 4.3

Comparison 4 CBT versus other therapies (short‐term), Outcome 3 PTSD avoidance.

Comparison 4 CBT versus other therapies (short‐term), Outcome 4 PTSD hyperarousal.
Figuras y tablas -
Analysis 4.4

Comparison 4 CBT versus other therapies (short‐term), Outcome 4 PTSD hyperarousal.

Comparison 4 CBT versus other therapies (short‐term), Outcome 5 PTSD intrusion.
Figuras y tablas -
Analysis 4.5

Comparison 4 CBT versus other therapies (short‐term), Outcome 5 PTSD intrusion.

Comparison 4 CBT versus other therapies (short‐term), Outcome 6 Anxiety total symptoms.
Figuras y tablas -
Analysis 4.6

Comparison 4 CBT versus other therapies (short‐term), Outcome 6 Anxiety total symptoms.

Comparison 4 CBT versus other therapies (short‐term), Outcome 7 Depression.
Figuras y tablas -
Analysis 4.7

Comparison 4 CBT versus other therapies (short‐term), Outcome 7 Depression.

Comparison 4 CBT versus other therapies (short‐term), Outcome 8 Behaviour ‐ total.
Figuras y tablas -
Analysis 4.8

Comparison 4 CBT versus other therapies (short‐term), Outcome 8 Behaviour ‐ total.

Comparison 4 CBT versus other therapies (short‐term), Outcome 9 Behaviour ‐ internalising.
Figuras y tablas -
Analysis 4.9

Comparison 4 CBT versus other therapies (short‐term), Outcome 9 Behaviour ‐ internalising.

Comparison 4 CBT versus other therapies (short‐term), Outcome 10 Behaviour ‐ externalising.
Figuras y tablas -
Analysis 4.10

Comparison 4 CBT versus other therapies (short‐term), Outcome 10 Behaviour ‐ externalising.

Comparison 4 CBT versus other therapies (short‐term), Outcome 11 Function.
Figuras y tablas -
Analysis 4.11

Comparison 4 CBT versus other therapies (short‐term), Outcome 11 Function.

Comparison 4 CBT versus other therapies (short‐term), Outcome 12 Loss to follow‐up.
Figuras y tablas -
Analysis 4.12

Comparison 4 CBT versus other therapies (short‐term), Outcome 12 Loss to follow‐up.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 1 PTSD total symptoms.
Figuras y tablas -
Analysis 5.1

Comparison 5 CBT versus other therapies (medium‐term), Outcome 1 PTSD total symptoms.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 2 Anxiety total symptoms.
Figuras y tablas -
Analysis 5.2

Comparison 5 CBT versus other therapies (medium‐term), Outcome 2 Anxiety total symptoms.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 3 Depression.
Figuras y tablas -
Analysis 5.3

Comparison 5 CBT versus other therapies (medium‐term), Outcome 3 Depression.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 4 Behaviour ‐ total.
Figuras y tablas -
Analysis 5.4

Comparison 5 CBT versus other therapies (medium‐term), Outcome 4 Behaviour ‐ total.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 5 Behaviour ‐ internalising.
Figuras y tablas -
Analysis 5.5

Comparison 5 CBT versus other therapies (medium‐term), Outcome 5 Behaviour ‐ internalising.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 6 Behaviour ‐ externalising.
Figuras y tablas -
Analysis 5.6

Comparison 5 CBT versus other therapies (medium‐term), Outcome 6 Behaviour ‐ externalising.

Comparison 5 CBT versus other therapies (medium‐term), Outcome 7 Loss to follow‐up.
Figuras y tablas -
Analysis 5.7

Comparison 5 CBT versus other therapies (medium‐term), Outcome 7 Loss to follow‐up.

Comparison 6 CBT versus other therapies (long‐term), Outcome 1 Behaviour ‐ internalising.
Figuras y tablas -
Analysis 6.1

Comparison 6 CBT versus other therapies (long‐term), Outcome 1 Behaviour ‐ internalising.

Comparison 6 CBT versus other therapies (long‐term), Outcome 2 Behaviour ‐ externalising.
Figuras y tablas -
Analysis 6.2

Comparison 6 CBT versus other therapies (long‐term), Outcome 2 Behaviour ‐ externalising.

Comparison 6 CBT versus other therapies (long‐term), Outcome 3 Loss to follow‐up.
Figuras y tablas -
Analysis 6.3

Comparison 6 CBT versus other therapies (long‐term), Outcome 3 Loss to follow‐up.

Comparison 7 Subgroup analysis: Individual versus group therapy, Outcome 1 PTSD total symptoms.
Figuras y tablas -
Analysis 7.1

Comparison 7 Subgroup analysis: Individual versus group therapy, Outcome 1 PTSD total symptoms.

Comparison 8 Subgroup analysis: Child versus mother and child therapy, Outcome 1 PTSD total symptoms.
Figuras y tablas -
Analysis 8.1

Comparison 8 Subgroup analysis: Child versus mother and child therapy, Outcome 1 PTSD total symptoms.

Comparison 9 Subgroup analysis: type of trauma, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 9.1

Comparison 9 Subgroup analysis: type of trauma, Outcome 1 PTSD diagnosis.

Comparison 9 Subgroup analysis: type of trauma, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 9.2

Comparison 9 Subgroup analysis: type of trauma, Outcome 2 PTSD total symptoms.

Comparison 10 Subgroup analysis: symptomatic participants, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 10.1

Comparison 10 Subgroup analysis: symptomatic participants, Outcome 1 PTSD diagnosis.

Comparison 10 Subgroup analysis: symptomatic participants, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 10.2

Comparison 10 Subgroup analysis: symptomatic participants, Outcome 2 PTSD total symptoms.

Comparison 11 Sensitivity analysis: type of control, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 11.1

Comparison 11 Sensitivity analysis: type of control, Outcome 1 PTSD diagnosis.

Comparison 11 Sensitivity analysis: type of control, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 11.2

Comparison 11 Sensitivity analysis: type of control, Outcome 2 PTSD total symptoms.

Comparison 12 Sensitivity analysis: best‐/worst‐case analysis, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 12.1

Comparison 12 Sensitivity analysis: best‐/worst‐case analysis, Outcome 1 PTSD diagnosis.

Comparison 13 Sensitivity analysis: cluster‐randomisation, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 13.1

Comparison 13 Sensitivity analysis: cluster‐randomisation, Outcome 1 PTSD diagnosis.

Comparison 13 Sensitivity analysis: cluster‐randomisation, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 13.2

Comparison 13 Sensitivity analysis: cluster‐randomisation, Outcome 2 PTSD total symptoms.

Comparison 14 Sensitivity analysis: performance bias, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 14.1

Comparison 14 Sensitivity analysis: performance bias, Outcome 1 PTSD diagnosis.

Comparison 14 Sensitivity analysis: performance bias, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 14.2

Comparison 14 Sensitivity analysis: performance bias, Outcome 2 PTSD total symptoms.

Comparison 15 Sensitivity analysis: detection bias, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 15.1

Comparison 15 Sensitivity analysis: detection bias, Outcome 1 PTSD diagnosis.

Comparison 15 Sensitivity analysis: detection bias, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 15.2

Comparison 15 Sensitivity analysis: detection bias, Outcome 2 PTSD total symptoms.

Comparison 16 Sensitivity analysis: attrition bias, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 16.1

Comparison 16 Sensitivity analysis: attrition bias, Outcome 1 PTSD diagnosis.

Comparison 16 Sensitivity analysis: attrition bias, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 16.2

Comparison 16 Sensitivity analysis: attrition bias, Outcome 2 PTSD total symptoms.

Comparison 17 Sensitivity analysis: selection bias, Outcome 1 PTSD diagnosis.
Figuras y tablas -
Analysis 17.1

Comparison 17 Sensitivity analysis: selection bias, Outcome 1 PTSD diagnosis.

Comparison 17 Sensitivity analysis: selection bias, Outcome 2 PTSD total symptoms.
Figuras y tablas -
Analysis 17.2

Comparison 17 Sensitivity analysis: selection bias, Outcome 2 PTSD total symptoms.

Summary of findings for the main comparison. Psychological therapies versus wait list, treatment as usual or no treatment for children and adolescents exposed to trauma (short‐term)

Patient or population: children and adolescents exposed to trauma
Setting: three hospitals and fourteen community/outpatient settings (including eight schools, a trauma clinic, child support services, foster care and youth support services) in the US (6), Australia (2), Democratic Republic of Congo (2), Israel (2), the Palestinian territories (2), Bosnia(1), Canada (1), and Indonesia (1).
Intervention: all psychological therapies
Comparison: control (short‐term)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with control (short‐term)

Risk with all psychotherapies

PTSD diagnosis

Study population

OR 0.51
(0.34 to 0.77)

874
(5 studies)

⊕⊝⊝⊝
Very lowa,b,c

367 per 1000

228 per 1000
(165 to 309)

Moderate

345 per 1000

212 per 1000
(152 to 288)

PTSD total symptoms

Mean PTSD total symptoms in the intervention group 0.42 standard deviations undefined fewer (0.61 fewer to 0.24 fewer)

Moderate effect size

2051
(15 studies)

⊕⊕⊝⊝
Lowd,e

*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and relative effect of the intervention (and its 95% CI)
CI: confidence interval; OR: odds ratio; RR: risk ratio

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect but may be substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aParticipants are likely to have been aware of whether they received the active or inactive intervention in all studies, and diagnosis was based on self reported measures in 2 studies
bSignificant difference between the 2 psychological therapies included in this analysis (i.e. CBT and family therapy) (I2 = 69%)
cOnly 3 included studies with a relatively small overall sample number of 352

dParticipants were likely to have been aware of whether they received active or inactive intervention in all but one study, and scores were based on self reported measures in 10 studies

eSubstantial heterogeneity between different types of psychological therapy (I2 = 71%)

Figuras y tablas -
Summary of findings for the main comparison. Psychological therapies versus wait list, treatment as usual or no treatment for children and adolescents exposed to trauma (short‐term)
Summary of findings 2. CBT versus other psychological therapies for children and adolescents exposed to trauma (short‐term)

Patient or population: children and adolescents exposed to trauma
Setting: All seven studies were done in community or outpatient settings including child trauma (2) or psychiatric (2) services, child support services (1), domestic violence service (1) and school (1) in the US (4), Netherlands (2), and Iran (1).
Intervention: CBT
Comparison: other psychological therapies (short‐term)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

Numer of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with other therapies (short‐term)

Risk with CBT

PTSD diagnosis

Study population

OR 0.74
(0.29 to 1.91)

160
(2 studies)

⊕⊝⊝⊝
Very lowa,b

141 per 1000

108 per 1000
(45 to 239)

Moderate

111 per 1000

85 per 1000
(35 to 193)

PTSD total symptoms

Mean PTSD total symptoms in the intervention group 0.24 standard deviations undefined fewer (0.42 fewer to 0.05 fewer)

Small effect size

466
(7 studies)

⊕⊕⊕⊝
Moderatec

*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and relative effect of the intervention (and its 95% CI)
CI: confidence interval; OR: odds ratio; RR: risk ratio

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aParticipants are likely to have been aware of whether they received active or inactive intervention in both studies, and diagnosis was based on self reported measures in both
bOnly 2 included studies with a relatively small overall sample number of 287

cParticipants are likely to have been aware of whether they received active or inactive intervention in all studies, and scores were based on self reported measures in 4 studies

Figuras y tablas -
Summary of findings 2. CBT versus other psychological therapies for children and adolescents exposed to trauma (short‐term)
Table 1. Data from Church 2012

Outcome

Group

n

Mean

SD

PTSD symptoms

One month

Exposure therapy

8

3.38

2.60

Control

8

31.38

3.84

Avoidance

One month

Exposure therapy

8

2.88

2.62

Control

8

20.25

2.38

Intrusion

One month

Exposure therapy

8

0.50

0.50

Control

8

11.13

2.93

Figuras y tablas -
Table 1. Data from Church 2012
Table 2. Data from Damra 2014

Outcome

Group

n

Mean

SD

PTSD symptoms

Post therapy

TF‐CBT

9

13.00

1.12

Control

9

24.20

1.54

PTSD symptoms

4 months

TF‐CBT

9

11.88

1.96

Control

9

23.98

1.47

Figuras y tablas -
Table 2. Data from Damra 2014
Table 3. Data from McMullen 2013

Outcome

Group

n

Mean

SD

PTSD symptoms

Post therapy

TF‐CBT

24

10.6

4.5

Control

24

34.8

11.6

Conduct Problems

Post therapy

TF‐CBT

24

0.7

0.9

Control

24

7.1

7.0

Figuras y tablas -
Table 3. Data from McMullen 2013
Comparison 1. All psychotherapies versus control (short‐term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

5

874

Odds Ratio (M‐H, Random, 95% CI)

0.51 [0.34, 0.77]

1.1 CBT

3

769

Odds Ratio (M‐H, Random, 95% CI)

0.59 [0.43, 0.80]

1.2 EMDR

1

40

Odds Ratio (M‐H, Random, 95% CI)

0.2 [0.01, 4.44]

1.3 Family therapy

1

65

Odds Ratio (M‐H, Random, 95% CI)

0.11 [0.02, 0.56]

2 PTSD total symptoms Show forest plot

15

2051

Std. Mean Difference (IV, Random, 95% CI)

‐0.42 [‐0.61, ‐0.24]

2.1 CBT

6

1329

Std. Mean Difference (IV, Random, 95% CI)

‐0.37 [‐0.55, ‐0.19]

2.2 EMDR

1

24

Std. Mean Difference (IV, Random, 95% CI)

‐0.77 [‐1.61, 0.06]

2.3 Family therapy

2

95

Std. Mean Difference (IV, Random, 95% CI)

‐0.53 [‐0.94, ‐0.12]

2.4 Narrative

1

64

Std. Mean Difference (IV, Random, 95% CI)

0.23 [‐0.26, 0.72]

2.5 Psychoeducation

2

215

Std. Mean Difference (IV, Random, 95% CI)

‐0.19 [‐0.69, 0.30]

2.6 Supportive therapy

2

272

Std. Mean Difference (IV, Random, 95% CI)

‐0.40 [‐0.95, 0.15]

2.7 CBT + narrative therapy

1

52

Std. Mean Difference (IV, Random, 95% CI)

‐1.96 [‐2.63, ‐1.29]

3 PTSD avoidance Show forest plot

2

205

Std. Mean Difference (IV, Random, 95% CI)

‐0.02 [‐0.29, 0.26]

3.1 Narrative

1

158

Std. Mean Difference (IV, Random, 95% CI)

0.05 [‐0.27, 0.36]

3.2 Psychoeducation

1

47

Std. Mean Difference (IV, Random, 95% CI)

‐0.23 [‐0.80, 0.35]

4 PTSD hyperarousal Show forest plot

2

205

Std. Mean Difference (IV, Random, 95% CI)

0.05 [‐0.22, 0.32]

4.1 Narrative

1

158

Std. Mean Difference (IV, Random, 95% CI)

0.10 [‐0.21, 0.41]

4.2 Psychoeducation

1

47

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.70, 0.45]

5 PTSD intrusion Show forest plot

2

205

Std. Mean Difference (IV, Random, 95% CI)

0.11 [‐0.16, 0.39]

5.1 Narrative

1

158

Std. Mean Difference (IV, Random, 95% CI)

0.15 [‐0.16, 0.46]

5.2 Psychoeducation

1

47

Std. Mean Difference (IV, Random, 95% CI)

‐0.02 [‐0.59, 0.55]

6 Anxiety total symptoms Show forest plot

7

959

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.26, 0.00]

6.1 CBT

2

557

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.30, 0.04]

6.2 Counselling

1

130

Std. Mean Difference (IV, Random, 95% CI)

‐0.20 [‐0.56, 0.16]

6.3 EMDR

1

40

Std. Mean Difference (IV, Random, 95% CI)

‐0.66 [‐1.30, ‐0.03]

6.4 Exposure

1

65

Std. Mean Difference (IV, Random, 95% CI)

0.01 [‐0.48, 0.51]

6.5 Narrative

1

111

Std. Mean Difference (IV, Random, 95% CI)

‐0.21 [‐0.58, 0.17]

6.6 Psychoeducation

1

56

Std. Mean Difference (IV, Random, 95% CI)

0.32 [‐0.21, 0.85]

7 Anxiety ‐ state Show forest plot

2

70

Std. Mean Difference (IV, Random, 95% CI)

‐0.64 [‐1.12, ‐0.16]

7.1 CBT

1

46

Std. Mean Difference (IV, Random, 95% CI)

‐0.71 [‐1.31, ‐0.12]

7.2 EMDR

1

24

Std. Mean Difference (IV, Random, 95% CI)

‐0.51 [‐1.33, 0.31]

8 Anxiety ‐ trait Show forest plot

2

70

Std. Mean Difference (IV, Random, 95% CI)

‐0.34 [‐0.81, 0.14]

8.1 CBT

1

46

Std. Mean Difference (IV, Random, 95% CI)

‐0.36 [‐0.94, 0.22]

8.2 EMDR

1

24

Std. Mean Difference (IV, Random, 95% CI)

‐0.29 [‐1.10, 0.51]

9 Depression Show forest plot

13

1569

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.30, 0.04]

9.1 CBT

6

1191

Std. Mean Difference (IV, Random, 95% CI)

‐0.21 [‐0.42, ‐0.00]

9.2 EMDR

2

64

Std. Mean Difference (IV, Random, 95% CI)

‐0.39 [‐1.41, 0.64]

9.3 Exposure

1

52

Std. Mean Difference (IV, Random, 95% CI)

0.10 [‐0.45, 0.65]

9.4 Family therapy

1

30

Std. Mean Difference (IV, Random, 95% CI)

0.05 [‐0.66, 0.77]

9.5 Narrative

2

176

Std. Mean Difference (IV, Random, 95% CI)

0.13 [‐0.52, 0.77]

9.6 Psychoeducation

1

56

Std. Mean Difference (IV, Random, 95% CI)

0.09 [‐0.43, 0.62]

10 Behaviour ‐ total Show forest plot

3

166

Std. Mean Difference (IV, Random, 95% CI)

‐0.04 [‐0.51, 0.42]

10.1 EMDR

1

24

Std. Mean Difference (IV, Random, 95% CI)

‐0.44 [‐1.25, 0.37]

10.2 Exposure

1

77

Std. Mean Difference (IV, Random, 95% CI)

0.34 [‐0.11, 0.80]

10.3 Family therapy

1

65

Std. Mean Difference (IV, Random, 95% CI)

‐0.23 [‐0.72, 0.26]

11 Behaviour ‐ internalising Show forest plot

10

719

Std. Mean Difference (IV, Random, 95% CI)

‐0.04 [‐0.20, 0.13]

11.1 CBT

2

162

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.44, 0.18]

11.2 EMDR

2

64

Std. Mean Difference (IV, Random, 95% CI)

‐0.57 [‐1.07, ‐0.07]

11.3 Exposure

1

77

Std. Mean Difference (IV, Random, 95% CI)

0.38 [‐0.08, 0.84]

11.4 Family therapy

1

30

Std. Mean Difference (IV, Random, 95% CI)

0.32 [‐0.40, 1.04]

11.5 Narrative

2

180

Std. Mean Difference (IV, Random, 95% CI)

0.12 [‐0.18, 0.41]

11.6 Psychoeducation

2

206

Std. Mean Difference (IV, Random, 95% CI)

‐0.11 [‐0.38, 0.17]

12 Behaviour ‐ externalising Show forest plot

12

1174

Std. Mean Difference (IV, Random, 95% CI)

‐0.10 [‐0.33, 0.14]

12.1 CBT

3

565

Std. Mean Difference (IV, Random, 95% CI)

‐0.11 [‐0.28, 0.06]

12.2 EMDR

2

64

Std. Mean Difference (IV, Random, 95% CI)

‐0.55 [‐1.19, 0.10]

12.3 Exposure

1

77

Std. Mean Difference (IV, Random, 95% CI)

0.49 [0.03, 0.95]

12.4 Family therapy

1

30

Std. Mean Difference (IV, Random, 95% CI)

0.23 [‐0.49, 0.95]

12.5 Narrative

2

180

Std. Mean Difference (IV, Random, 95% CI)

0.20 [‐0.41, 0.81]

12.6 Psychoeducation

2

206

Std. Mean Difference (IV, Random, 95% CI)

‐0.03 [‐0.52, 0.46]

12.7 CBT + narrative therapy

1

52

Std. Mean Difference (IV, Random, 95% CI)

‐1.06 [‐1.64, ‐0.47]

13 Functional impairment Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

13.1 CBT

2

557

Std. Mean Difference (IV, Random, 95% CI)

‐0.41 [‐0.59, ‐0.24]

14 Quality of life Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

14.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

15 Loss to follow‐up Show forest plot

26

3872

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.69, 1.39]

15.1 CBT

14

2913

Risk Ratio (M‐H, Random, 95% CI)

0.87 [0.47, 1.62]

15.2 Counselling

1

164

Risk Ratio (M‐H, Random, 95% CI)

0.56 [0.30, 1.03]

15.3 EMDR

2

92

Risk Ratio (M‐H, Random, 95% CI)

1.64 [0.48, 5.59]

15.4 Exposure

1

16

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

15.5 Family therapy

2

105

Risk Ratio (M‐H, Random, 95% CI)

1.44 [0.48, 4.30]

15.6 Narrative

2

280

Risk Ratio (M‐H, Random, 95% CI)

0.87 [0.32, 2.39]

15.7 Psychoeducation

3

274

Risk Ratio (M‐H, Random, 95% CI)

1.21 [0.75, 1.96]

15.8 Psychodrama

1

28

Risk Ratio (M‐H, Random, 95% CI)

1.5 [0.29, 7.65]

Figuras y tablas -
Comparison 1. All psychotherapies versus control (short‐term)
Comparison 2. All psychotherapies versus control (medium‐term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

4

742

Odds Ratio (M‐H, Random, 95% CI)

0.66 [0.26, 1.69]

1.1 CBT

2

570

Odds Ratio (M‐H, Random, 95% CI)

0.49 [0.09, 2.61]

1.2 Debriefing

1

132

Odds Ratio (M‐H, Random, 95% CI)

1.31 [0.47, 3.68]

1.3 EMDR

1

40

Odds Ratio (M‐H, Random, 95% CI)

0.35 [0.01, 9.13]

2 PTSD total symptoms Show forest plot

12

2337

Std. Mean Difference (IV, Random, 95% CI)

‐0.17 [‐0.38, 0.05]

2.1 CBT

5

1701

Std. Mean Difference (IV, Random, 95% CI)

‐0.34 [‐0.72, 0.03]

2.2 Debriefing

2

231

Std. Mean Difference (IV, Random, 95% CI)

0.04 [‐0.22, 0.30]

2.3 Family therapy

2

141

Std. Mean Difference (IV, Random, 95% CI)

‐0.06 [‐0.39, 0.27]

2.4 Narrative

1

64

Std. Mean Difference (IV, Random, 95% CI)

0.23 [‐0.26, 0.73]

2.5 Psychoeducation

1

56

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.65, 0.40]

2.6 Supportive therapy

1

144

Std. Mean Difference (IV, Random, 95% CI)

‐0.21 [‐0.54, 0.12]

3 PTSD ‐ avoidance Show forest plot

2

243

Std. Mean Difference (IV, Fixed, 95% CI)

0.04 [‐0.22, 0.29]

3.1 Debriefing

1

132

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.08 [‐0.42, 0.26]

3.2 Family therapy

1

111

Std. Mean Difference (IV, Fixed, 95% CI)

0.18 [‐0.20, 0.55]

4 PTSD ‐ hyperarousal Show forest plot

2

243

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.43, 0.17]

4.1 Debriefing

1

132

Std. Mean Difference (IV, Random, 95% CI)

0.01 [‐0.33, 0.35]

4.2 Family therapy

1

111

Std. Mean Difference (IV, Random, 95% CI)

‐0.29 [‐0.67, 0.09]

5 PTSD ‐ intrusion Show forest plot

2

243

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.04 [‐0.29, 0.21]

5.1 Debriefing

1

132

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.05 [‐0.39, 0.29]

5.2 Family therapy

1

111

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.03 [‐0.40, 0.35]

6 Anxiety total symptoms Show forest plot

7

1470

Std. Mean Difference (IV, Random, 95% CI)

‐0.10 [‐0.20, 0.00]

6.1 CBT

3

1131

Std. Mean Difference (IV, Random, 95% CI)

‐0.07 [‐0.19, 0.04]

6.2 Debriefing

1

132

Std. Mean Difference (IV, Random, 95% CI)

‐0.08 [‐0.42, 0.27]

6.3 EMDR

1

40

Std. Mean Difference (IV, Random, 95% CI)

‐0.72 [‐1.36, ‐0.07]

6.4 Psychoeducation

1

56

Std. Mean Difference (IV, Random, 95% CI)

‐0.21 [‐0.73, 0.32]

6.5 Narrative

1

111

Std. Mean Difference (IV, Random, 95% CI)

‐0.17 [‐0.54, 0.21]

7 Anxiety ‐ state Show forest plot

1

Std. Mean Difference (IV, Fixed, 95% CI)

Totals not selected

7.1 CBT

1

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Anxiety ‐ trait Show forest plot

2

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

8.1 CBT

2

101

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.45 [‐0.85, ‐0.05]

9 Depression Show forest plot

13

2191

Std. Mean Difference (IV, Random, 95% CI)

‐0.07 [‐0.22, 0.07]

9.1 CBT

8

1810

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.31, 0.07]

9.2 Debriefing

2

231

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.38, 0.14]

9.3 Family therapy

1

30

Std. Mean Difference (IV, Random, 95% CI)

0.34 [‐0.38, 1.06]

9.4 Narrative

1

64

Std. Mean Difference (IV, Random, 95% CI)

0.34 [‐0.15, 0.84]

9.5 Psychoeducation

1

56

Std. Mean Difference (IV, Random, 95% CI)

‐0.14 [‐0.67, 0.38]

10 Behaviour ‐ total Show forest plot

3

281

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐0.43, 0.04]

10.1 Debriefing

1

132

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.28 [‐0.62, 0.06]

10.2 Family therapy

1

50

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.37 [‐0.93, 0.19]

10.3 Narrative

1

99

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.39, 0.39]

11 Behaviour ‐ internalising Show forest plot

4

291

Std. Mean Difference (IV, Random, 95% CI)

0.01 [‐0.25, 0.28]

11.1 EMDR

1

40

Std. Mean Difference (IV, Random, 95% CI)

‐0.50 [‐1.13, 0.14]

11.2 Family therapy

1

30

Std. Mean Difference (IV, Random, 95% CI)

0.0 [‐0.72, 0.72]

11.3 Narrative

2

221

Std. Mean Difference (IV, Random, 95% CI)

0.13 [‐0.13, 0.40]

12 Behaviour ‐ externalising Show forest plot

5

694

Std. Mean Difference (IV, Random, 95% CI)

0.02 [‐0.32, 0.35]

12.1 CBT

1

403

Std. Mean Difference (IV, Random, 95% CI)

0.07 [‐0.13, 0.27]

12.2 EMDR

1

40

Std. Mean Difference (IV, Random, 95% CI)

1.00 [‐1.66, ‐0.33]

12.3 Family therapy

1

30

Std. Mean Difference (IV, Random, 95% CI)

‐0.01 [‐0.72, 0.71]

12.4 Narrative

2

221

Std. Mean Difference (IV, Random, 95% CI)

0.31 [0.05, 0.58]

13 Function Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

13.1 CBT

3

814

Std. Mean Difference (IV, Random, 95% CI)

‐0.46 [‐0.88, ‐0.05]

14 Quality of life Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

14.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

15 Loss to follow‐up Show forest plot

20

3663

Odds Ratio (M‐H, Fixed, 95% CI)

1.00 [0.82, 1.21]

15.1 CBT

11

2856

Odds Ratio (M‐H, Fixed, 95% CI)

1.01 [0.81, 1.27]

15.2 Counselling

1

23

Odds Ratio (M‐H, Fixed, 95% CI)

7.0 [0.32, 152.95]

15.3 Debriefing

1

158

Odds Ratio (M‐H, Fixed, 95% CI)

0.76 [0.33, 1.76]

15.4 EMDR

1

65

Odds Ratio (M‐H, Fixed, 95% CI)

1.41 [0.52, 3.84]

15.5 Family therapy

1

75

Odds Ratio (M‐H, Fixed, 95% CI)

1.28 [0.48, 3.39]

15.6 Narrative

2

171

Odds Ratio (M‐H, Fixed, 95% CI)

0.70 [0.16, 2.99]

15.7 Psychoeducation

2

244

Odds Ratio (M‐H, Fixed, 95% CI)

0.77 [0.40, 1.47]

15.8 Other

1

71

Odds Ratio (M‐H, Fixed, 95% CI)

0.90 [0.29, 2.73]

Figuras y tablas -
Comparison 2. All psychotherapies versus control (medium‐term)
Comparison 3. All psychotherapies versus control (long‐term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

1

Odds Ratio (M‐H, Random, 95% CI)

Totals not selected

1.1 Narrative

1

Odds Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

2 PTSD total symptoms Show forest plot

2

141

Std. Mean Difference (IV, Random, 95% CI)

0.17 [‐0.28, 0.62]

2.1 Exposure

1

77

Std. Mean Difference (IV, Random, 95% CI)

0.39 [‐0.07, 0.85]

2.2 Narrative

1

64

Std. Mean Difference (IV, Random, 95% CI)

‐0.07 [‐0.56, 0.42]

3 Anxiety Show forest plot

2

176

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.41, 0.18]

3.1 Exposure

1

65

Std. Mean Difference (IV, Random, 95% CI)

‐0.30 [‐0.80, 0.19]

3.2 Narrative

1

111

Std. Mean Difference (IV, Random, 95% CI)

‐0.01 [‐0.39, 0.36]

4 Depression Show forest plot

3

152

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.24 [‐0.56, 0.08]

4.1 CBT

1

36

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.59 [‐1.27, 0.09]

4.2 Exposure

1

52

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.29 [‐0.84, 0.26]

4.3 Narrative

1

64

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.02 [‐0.51, 0.47]

5 Behaviour ‐ total Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

5.1 Exposure

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

6 Behaviour ‐ internalising Show forest plot

2

141

Std. Mean Difference (IV, Random, 95% CI)

0.04 [‐0.51, 0.59]

6.1 Exposure

1

77

Std. Mean Difference (IV, Random, 95% CI)

0.31 [‐0.15, 0.77]

6.2 Narrative

1

64

Std. Mean Difference (IV, Random, 95% CI)

‐0.25 [‐0.75, 0.24]

7 Behaviour ‐ externalising Show forest plot

3

298

Std. Mean Difference (IV, Random, 95% CI)

0.28 [‐0.05, 0.60]

7.1 Exposure

1

77

Std. Mean Difference (IV, Random, 95% CI)

0.51 [0.04, 0.97]

7.2 Narrative

2

221

Std. Mean Difference (IV, Random, 95% CI)

0.17 [‐0.30, 0.64]

8 Loss to follow‐up Show forest plot

2

120

Odds Ratio (M‐H, Random, 95% CI)

0.45 [0.15, 1.32]

8.1 CBT

1

50

Odds Ratio (M‐H, Random, 95% CI)

0.29 [0.08, 1.09]

8.2 Narrative

1

70

Odds Ratio (M‐H, Random, 95% CI)

0.88 [0.17, 4.71]

Figuras y tablas -
Comparison 3. All psychotherapies versus control (long‐term)
Comparison 4. CBT versus other therapies (short‐term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

2

160

Odds Ratio (M‐H, Random, 95% CI)

0.74 [0.29, 1.91]

1.1 EMDR

1

36

Odds Ratio (M‐H, Random, 95% CI)

1.0 [0.06, 17.33]

1.2 Supportive therapy

1

124

Odds Ratio (M‐H, Random, 95% CI)

0.71 [0.26, 1.95]

2 PTSD total symptoms Show forest plot

7

466

Std. Mean Difference (IV, Random, 95% CI)

‐0.24 [‐0.42, ‐0.05]

2.1 EMDR

2

62

Std. Mean Difference (IV, Random, 95% CI)

0.06 [‐0.44, 0.56]

2.2 Play therapy

1

26

Std. Mean Difference (IV, Random, 95% CI)

0.21 [‐0.56, 0.98]

2.3 Supportive therapies

4

378

Std. Mean Difference (IV, Random, 95% CI)

‐0.32 [‐0.53, ‐0.12]

3 PTSD avoidance Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

3.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

4 PTSD hyperarousal Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

4.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

5 PTSD intrusion Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

5.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

6 Anxiety total symptoms Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

6.1 Supportive therapy

2

230

Std. Mean Difference (IV, Random, 95% CI)

‐0.48 [‐0.74, ‐0.22]

7 Depression Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

7.1 Supportive therapy

2

237

Std. Mean Difference (IV, Random, 95% CI)

‐0.14 [‐0.42, 0.14]

8 Behaviour ‐ total Show forest plot

3

182

Std. Mean Difference (IV, Random, 95% CI)

0.02 [‐0.27, 0.31]

8.1 EMDR

1

14

Std. Mean Difference (IV, Random, 95% CI)

‐0.44 [‐1.50, 0.63]

8.2 Supportive therapy

2

168

Std. Mean Difference (IV, Random, 95% CI)

0.05 [‐0.25, 0.36]

9 Behaviour ‐ internalising Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

9.1 Supportive therapy

3

235

Std. Mean Difference (IV, Random, 95% CI)

‐0.25 [‐0.79, 0.28]

10 Behaviour ‐ externalising Show forest plot

3

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

10.1 Supportive therapy

3

235

Std. Mean Difference (IV, Random, 95% CI)

‐0.31 [‐0.58, ‐0.05]

11 Function Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

11.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

12 Loss to follow‐up Show forest plot

8

544

Odds Ratio (M‐H, Random, 95% CI)

0.69 [0.41, 1.18]

12.1 EMDR

2

64

Odds Ratio (M‐H, Random, 95% CI)

0.76 [0.23, 2.52]

12.2 Play therapy

1

31

Odds Ratio (M‐H, Random, 95% CI)

0.08 [0.00, 1.56]

12.3 Supportive therapy

5

449

Odds Ratio (M‐H, Random, 95% CI)

0.74 [0.38, 1.43]

Figuras y tablas -
Comparison 4. CBT versus other therapies (short‐term)
Comparison 5. CBT versus other therapies (medium‐term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD total symptoms Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 Supportive therapy

2

223

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.43, 0.11]

2 Anxiety total symptoms Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

2.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 Depression Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

3.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

4 Behaviour ‐ total Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

4.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

5 Behaviour ‐ internalising Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

5.1 Supportive therapy

2

178

Std. Mean Difference (IV, Random, 95% CI)

‐0.05 [‐0.36, 0.26]

6 Behaviour ‐ externalising Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

6.1 Supportive therapy

2

178

Std. Mean Difference (IV, Random, 95% CI)

‐0.06 [‐0.37, 0.25]

7 Loss to follow‐up Show forest plot

1

Odds Ratio (M‐H, Random, 95% CI)

Totals not selected

7.1 Supportive therapy

1

Odds Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 5. CBT versus other therapies (medium‐term)
Comparison 6. CBT versus other therapies (long‐term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Behaviour ‐ internalising Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

1.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Behaviour ‐ externalising Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

2.1 Supportive therapy

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 Loss to follow‐up Show forest plot

1

Odds Ratio (M‐H, Random, 95% CI)

Totals not selected

3.1 Supportive therapy

1

Odds Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 6. CBT versus other therapies (long‐term)
Comparison 7. Subgroup analysis: Individual versus group therapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD total symptoms Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

1.1 Short‐term

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 7. Subgroup analysis: Individual versus group therapy
Comparison 8. Subgroup analysis: Child versus mother and child therapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD total symptoms Show forest plot

1

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

1.1 Short‐term

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

1.2 Medium‐term

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

1.3 Long‐term

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 8. Subgroup analysis: Child versus mother and child therapy
Comparison 9. Subgroup analysis: type of trauma

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

6

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Community violence

3

769

Odds Ratio (M‐H, Random, 95% CI)

0.59 [0.43, 0.80]

1.2 Interpersonal violence

1

65

Odds Ratio (M‐H, Random, 95% CI)

0.11 [0.02, 0.56]

1.3 Natural disaster

1

166

Odds Ratio (M‐H, Random, 95% CI)

0.16 [0.06, 0.45]

1.4 Physical trauma

1

132

Odds Ratio (M‐H, Random, 95% CI)

1.31 [0.47, 3.68]

2 PTSD total symptoms Show forest plot

18

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Community violence

8

2170

Std. Mean Difference (IV, Random, 95% CI)

‐0.24 [‐0.41, ‐0.06]

2.2 Interpersonal violence

1

65

Std. Mean Difference (IV, Random, 95% CI)

‐0.61 [‐1.11, ‐0.11]

2.3 Life‐threatening illness

1

111

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.50, 0.26]

2.4 Maltreatment

1

142

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.45, 0.21]

2.5 Natural disaster

1

166

Std. Mean Difference (IV, Random, 95% CI)

‐1.27 [‐1.60, ‐0.94]

2.6 Physical trauma

4

311

Std. Mean Difference (IV, Random, 95% CI)

‐0.02 [‐0.29, 0.26]

2.7 Sexual abuse

2

76

Std. Mean Difference (IV, Random, 95% CI)

‐0.67 [‐1.18, ‐0.16]

Figuras y tablas -
Comparison 9. Subgroup analysis: type of trauma
Comparison 10. Subgroup analysis: symptomatic participants

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Symptoms not stated

5

999

Odds Ratio (M‐H, Random, 95% CI)

0.41 [0.20, 0.83]

1.2 Symptomatic

2

197

Odds Ratio (M‐H, Random, 95% CI)

0.64 [0.32, 1.25]

2 PTSD total symptoms Show forest plot

21

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Symptoms not stated

12

1648

Std. Mean Difference (IV, Random, 95% CI)

‐0.41 [‐0.68, ‐0.13]

2.2 Symptomatic

9

1639

Std. Mean Difference (IV, Random, 95% CI)

‐0.30 [‐0.53, ‐0.06]

Figuras y tablas -
Comparison 10. Subgroup analysis: symptomatic participants
Comparison 11. Sensitivity analysis: type of control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Inactive control

5

1067

Odds Ratio (M‐H, Random, 95% CI)

0.53 [0.32, 0.88]

1.2 Active control

2

129

Odds Ratio (M‐H, Random, 95% CI)

0.23 [0.05, 1.14]

2 PTSD total symptoms Show forest plot

21

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Inactive control

15

2856

Std. Mean Difference (IV, Random, 95% CI)

‐0.40 [‐0.61, ‐0.19]

2.2 Active control

6

431

Std. Mean Difference (IV, Random, 95% CI)

‐0.25 [‐0.58, 0.09]

Figuras y tablas -
Comparison 11. Sensitivity analysis: type of control
Comparison 12. Sensitivity analysis: best‐/worst‐case analysis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Best case

7

1282

Odds Ratio (M‐H, Random, 95% CI)

0.52 [0.28, 0.99]

1.2 Worst case

7

1252

Odds Ratio (M‐H, Random, 95% CI)

0.64 [0.42, 0.98]

Figuras y tablas -
Comparison 12. Sensitivity analysis: best‐/worst‐case analysis
Comparison 13. Sensitivity analysis: cluster‐randomisation

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Cluster‐randomised

4

935

Odds Ratio (M‐H, Random, 95% CI)

0.46 [0.27, 0.76]

1.2 Individuals randomised

3

261

Odds Ratio (M‐H, Random, 95% CI)

0.47 [0.10, 2.19]

2 PTSD total symptoms Show forest plot

20

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Cluster‐randomised

7

2063

Std. Mean Difference (IV, Random, 95% CI)

‐0.40 [‐0.71, ‐0.10]

2.2 Individuals randomised

13

1172

Std. Mean Difference (IV, Random, 95% CI)

‐0.22 [‐0.38, ‐0.06]

Figuras y tablas -
Comparison 13. Sensitivity analysis: cluster‐randomisation
Comparison 14. Sensitivity analysis: performance bias

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Unclear risk

1

64

Odds Ratio (M‐H, Random, 95% CI)

0.56 [0.09, 3.62]

1.2 High risk

6

1132

Odds Ratio (M‐H, Random, 95% CI)

0.46 [0.27, 0.79]

2 PTSD total symptoms Show forest plot

21

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Unclear risk

1

64

Std. Mean Difference (IV, Random, 95% CI)

0.23 [‐0.26, 0.72]

2.2 High risk

20

3223

Std. Mean Difference (IV, Random, 95% CI)

‐0.39 [‐0.57, ‐0.20]

Figuras y tablas -
Comparison 14. Sensitivity analysis: performance bias
Comparison 15. Sensitivity analysis: detection bias

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Low risk

2

197

Odds Ratio (M‐H, Random, 95% CI)

0.41 [0.04, 4.68]

1.2 Unclear risk

1

64

Odds Ratio (M‐H, Random, 95% CI)

0.56 [0.09, 3.62]

1.3 High risk

4

935

Odds Ratio (M‐H, Random, 95% CI)

0.46 [0.27, 0.76]

2 PTSD total symptoms Show forest plot

21

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Low risk

1

132

Std. Mean Difference (IV, Random, 95% CI)

‐0.05 [‐0.39, 0.30]

2.2 Unclear risk

2

191

Std. Mean Difference (IV, Random, 95% CI)

‐0.03 [‐0.46, 0.40]

2.3 High risk

18

2964

Std. Mean Difference (IV, Random, 95% CI)

‐0.42 [‐0.62, ‐0.22]

Figuras y tablas -
Comparison 15. Sensitivity analysis: detection bias
Comparison 16. Sensitivity analysis: attrition bias

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Low risk

2

320

Odds Ratio (M‐H, Random, 95% CI)

0.27 [0.11, 0.65]

1.2 Unclear risk

3

329

Odds Ratio (M‐H, Random, 95% CI)

0.79 [0.45, 1.38]

1.3 High risk

2

547

Odds Ratio (M‐H, Random, 95% CI)

0.32 [0.06, 1.60]

2 PTSD total symptoms Show forest plot

21

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Low risk

7

1410

Std. Mean Difference (IV, Random, 95% CI)

‐0.38 [‐0.75, ‐0.01]

2.2 Unclear risk

9

1046

Std. Mean Difference (IV, Random, 95% CI)

‐0.36 [‐0.67, ‐0.05]

2.3 High risk

5

831

Std. Mean Difference (IV, Random, 95% CI)

‐0.30 [‐0.53, ‐0.06]

Figuras y tablas -
Comparison 16. Sensitivity analysis: attrition bias
Comparison 17. Sensitivity analysis: selection bias

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PTSD diagnosis Show forest plot

7

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Low risk

4

516

Odds Ratio (M‐H, Random, 95% CI)

0.46 [0.18, 1.15]

1.2 Unclear risk

2

547

Odds Ratio (M‐H, Random, 95% CI)

0.32 [0.06, 1.60]

1.3 High risk

1

133

Odds Ratio (M‐H, Random, 95% CI)

0.65 [0.32, 1.33]

2 PTSD total symptoms Show forest plot

21

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

2.1 Low risk

8

874

Std. Mean Difference (IV, Random, 95% CI)

‐0.57 [‐0.97, ‐0.17]

2.2 Unclear risk

13

2413

Std. Mean Difference (IV, Random, 95% CI)

‐0.22 [‐0.39, ‐0.06]

Figuras y tablas -
Comparison 17. Sensitivity analysis: selection bias